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Tuberculosis, a highly contagious disease, ranks as the second leading cause of 
death from an infectious disease, and remains a major global health problem. In 
2013, 9 million new cases were diagnosed and 1.5 million people died worldwide 
from tuberculosis. This dissertation aims at developing a new, ultrafine particle-
based efficient antibiotic delivery system for the treatment of tuberculosis. The 
carrier material to make the rifampicin (RIF)-loaded particles is a low molecular 
weight star-shaped polymer produced from glucosamine (molecular core building 
unit) and L-lactide (GluN-LLA). Stable particles with a very high 50% drug loading 
capacity were made via electrohydrodynamic atomization. Prolonged release 
(>14 days) of RIF from these particles is demonstrated. Drug release data fits the 
Korsmeyer-Peppas equation, which suggests the occurrence of a modified 
diffusion-controlled RIF release mechanism, and is also supported by differential 
scanning calorimetry and drug leaching tests. Cytotoxicity tests on 
Mycobacterium smegmatis showed that antibiotic-free GluN-LLA and polylactides 
(PLA) (reference material) particles did not show any significant anti-bacterial 
activity. The minimum inhibitory concentration and minimum bactericidal 
concentration values obtained for RIF-loaded particles showed 2- to 4-fold 
  
improvements in the anti-bacterial activity relative to the free drug. Cytotoxicity 
tests on macrophages indicated an increment in cell death as particle dose 
increased, but was not significantly affected by material type or particle size. 
Confocal microscopy was used to track internalization and localization of 
particles in the macrophages. GluN-LLA particles led to higher uptakes than the 
PLA particles. In addition, after phagocytosis, the GluN-LLA particles stayed in 
the cytoplasm and the particles showed a favorable long term drug release effect 
in killing intracellular bacteria compared to free RIF. The studies presented and 
discussed in this dissertation suggest that these drug carrier materials are 
potentially very attractive candidates for the development of high-payload, 
sustained-release antibiotic/resorbable polymer particle systems for treating 
bacterial lung infections. 
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1.1. Synopsis 
 
This dissertation explores a new, custom-made polymer system as a promising 
drug delivery vehicle. Nano- and microparticles for tuberculosis treatment have 
been chosen as model system. This highly branched L-lactide grafted 
glucosamine (GluN-LLA) oligomer [1] was therefore processed into nano- and 
microparticles, resulting in nearly monodisperse particle size distributions. In 
addition, particles made from linear low- and high-molecular weight (LMW, and 
HMW, respectively) poly (L-lactic acid) (PLA) were produced and studied for 
comparison purposes. The most effective first-line anti-tuberculosis drug, 
rifampicin (RIF), was encapsulated in these nano- and microparticles via 
electrohydrodynamic atomization (EHDA). Particles were prepared from non-
toxic or low-toxicity solvent solutions because fully biocompatible drug delivery 
systems are ultimately desired. Ethyl acetate, one of the better solvents in this 
class, has shown to be very effective for EHDA processing of L-lactide grafted 
chitosan [2]. For drug delivery applications, three of the most desirable traits of 
these GluN-LLA oligomers are their high solubility in EA, their tunable 
hydrophobicity-hydrophilicity balance via control of the length of the lactide 
substituents, and their LMWs 
 
One of the most important problems with the current treatment of tuberculosis is 
the low patient compliance that causes multidrug-resistant (MDR) tuberculosis, 
and usually leads to patient death. A suitable solution to this problem is the 
implementation of a system that prolongs the therapeutic effect of one dose. In 
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order to demonstrate the sustained release of RIF from the new drug delivery 
system, in vitro release studies of RIF were conducted. Cytotoxicity effects of L-
lactide, and GluN-LLA based particles were tested on macrophages. The 
bactericidal activity of encapsulated and free RIF toward the chosen model 
microorganism, Mycobacterium smegmatis (M. smegmatis), was evaluated. M. 
smegmatis, a non-pathogenic and fast growing specie (generation times of 3-4 
hours), shares 2,000 homologs with Mycobacterium tuberculosis (M. 
tuberculosis), which makes this microorganism the most accepted model to study 
M. tuberculosis [3]. The effects produced by the polymeric matrix were evidenced 
by the minimum inhibitory concentration (MIC) and minimum bactericidal 
concentration (MBC) values. Intracellular killing of M. smegmatis in 
macrophages, caused by RIF loaded particles, was also investigated. Confocal 
microscopy was used to determine the internalization and intracellular location of 
L-lactide and GluN-LLA based particles containing RIF into macrophages. Finally, 
the intracellular killing of M. Smegmatis in alveolar macrophages showed that the 
particles are able to maintain a sustained release of RIF into the cells with 
release rates affecting the bacteria death rate, further pointing to the potential of 
GluN-LLA as a possible new nanoparticle drug carrier for the treatment of 
tuberculosis.   
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1.2. Motivation: Why Tuberculosis 
 
Tuberculosis, a highly contagious disease caused by the M. tuberculosis, ranks 
as the second leading cause of death from an infectious disease worldwide, after 
human immunodeficiency virus (HIV). According to the last report of the World 
health Organization (WHO) [4], tuberculosis approximately has infected 9 million 
people in 2013. In the same year, 1.5 million people died from this disease, 
including 360,000 HIV-positive patients. An estimated 1.1 million (13%) of the 
total new cases were HIV-positive.  
 
Even though most cases of tuberculosis and death occur among men (60%) in 
their productive life stage, in 2013 there were an estimated 3.3 million new cases 
and 510000 deaths among women, and 550 000 infected with 80 000 death 
among children. These numbers reflect the high mortality of tuberculosis, which 
is unacceptably high given that most deaths are preventable. Tuberculosis can 
be cured in 90% of the cases that have access to the medication regimens of 
first-line drugs [4].    
 
WHO Global Tuberculosis Report 2014 includes data compiled from 202 
countries and territories. It shows that South-East Asia and Western Pacific 
Regions represents more than half (56%) of the estimated 9 million new cases in 
2013. India and China alone accounted for 24% and, 11% of the total number of 
cases, respectively. The African region originated 25% of all cases, and also had 
the highest rates of fatal cases.  
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1.2.1. Bacillus Mycobacterium Tuberculosis 
 
 
M. tuberculosis typically affects the lungs (pulmonary tuberculosis), but can affect 
other sites as well (extra-pulmonary disease), and is transmitted by aerosols from 
the lungs of coughing infected individuals. Exposure to these bacteria does not 
always translate into infection. It is estimated that bacteria is cleared by a robust 
innate immune response in 50% of the individuals exposed to M.tuberculosis. As 
for the rest of the infected population, only 5% progress toward the development 
of active tuberculosis, and the remaining 95% control the infection throughout 
their lives (latent tuberculosis) [5]. About one-third of the world’s population 
(approximately 2 billion people) has latent tuberculosis, which progresses to the 
active disease when a patient’s immune system is compromised by say, HIV 
infection, old age, immunosuppressive drug treatment, or re-infection [4–7].  
 
M. tuberculosis is a relatively slow-growing microorganism with a generation time 
of 24 hours. Infection is spread via airborne dissemination of aerosolized bacteria 
containing droplet nuclei of 1-5 µm [7]. M. tuberculosis bacteria that gain access 
to a new host via inhaled air can begin the replication process inside the alveolar 
macrophages after 2-3 weeks of infection. Macrophages usually ingest and trap 
pathogens in a phagosome, which is then subject to a series of fusion and fission 
events with the endocytic pathways that end in a phagosome-lysosome fusion. 
This process is known as phagosome maturation, in which phagosomes acquire 
the antimicrobial tools to eliminate the pathogen. These killing mechanisms 
include acidification (pH<5), production of antimicrobial peptides, generation of 
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reactive oxygen and nitrogen species, and degradative enzymes such as 
cathepsins. However, M. tuberculosis is able to modulate pH-reducing events in 
a maturing phagosome, which can result in a more basic phagolysomal pH, thus 
enhancing bacteria survival and facilitating dormancy. The general view is that M. 
tuberculosis arrests phagosomal maturation by inhibition of both lysosomal fusion 
and reduction of recruitment of vacuolar H+-ATPases. These manipulations over 
the normal course of phagosomal maturation result in a modest drop of 
intrasomal pH, which avoid bacteria killing and favors its replication [5,8].     
 
1.2.2.  Current Chemotherapy against Tuberculosis 
 
Mortality rates of tuberculosis fall between 50 to 80% in untreated patients and 
drop to 5% for individuals receiving an active therapy [4,7]. The current 
treatment, tuberculosis chemotherapy, requires six months of an extensive drug 
regimen of RIF, isoniazid (INH), pyrazinamide (PYZ), and ethambutol [7]. The 
treatment comprises the following two stages:  (1) an intensive 2-month daily use 
of the four drugs mentioned before followed by (2) a 4-month daily administration 
of RIF and INH. This long and intensive treatment is one of the main causes for 
low patient compliance, and failure to adhere to the prescribed drug regime has 
resulted in the significant emergence of drug resistant strains of M. tuberculosis. 
Multidrug-resistant (MDR) tuberculosis has become a complex problem due to 
the recent proliferation of such strains. Treatment of MDR tuberculosis takes 
longer than conventional treatment modalities (WHO recommends 20 months), 
and requires more expensive and toxic drugs with lower success rates [4,9,10].  
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1.2.3.  Rifampicin (RIF) 
   
Rifampicin (Figure 1.1, formula: C43H58N4O12) is a semisynthetic derivative of the 
rifamycins, which are a class of antibiotics derived from fermentation products of 
Nocardia mediterranei. RIF possesses a unique mechanism of action that 
confers it a high level of antibacterial activity and it is based on the inhibition of 
bacterial RNA polymerase. By this action, RIF stops bacterial growth in a wide 
range of bacteria, including mycobacterium tuberculosis [11].  
 
 
Figure 1.1 – Rifampicin Chemical Structure 
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1.2.4.  Need for New Approaches to Combat the Disease 
  
Usually, patients fail to take the prescribed medications with adequate regularity 
and duration. In spite of the fact that current anti-tuberculosis chemotherapy 
treatment is highly effective in killing M tuberculosis, it involves a multidrug 
regimen where patients have to take a significant number of pills daily (up to 
eight at one time) for a long time. This is the main reason for patient non-
compliance, but the appearance of side effects is also cited. With the current 
treatments, only a small fraction of the dosed antibiotics reach the target area, 
mainly because its first-pass metabolism decreases the amount of drug that gets 
into the blood stream. As a consequence, to achieve therapeutic levels large 
doses of drugs are normally needed, and the probability of patients experiencing 
side effects increases [12]. Hepatotoxicity, the most common side effects of anti-
tuberculosis drugs, generally leads to treatment withdrawal [7,13]. These 
difficulties associated with patient non-compliance are the main driver behind 
new research aimed at exploring new drug administration concepts. Multiple new 
drugs and vaccines are in the pipeline or are being investigated nowadays, but 
neither route guarantees success [14], nor do they go against conventional 
treatment paradigms.  
 
An alternative strategy to current treatment approaches is to encapsulate anti-
tuberculosis drugs in nano- or microparticles made from biodegradable polymers. 
For instance, a very effective treatment should target alveolar macrophages 
where M. tuberculosis is harboring via suppression of the phagosome-lysosome 
10 
 
fusion process [15]. Since alveolar macrophages are one of the first lines of 
defense against entry of external particles including microbial invasion, 
macrophages targeting is generally accomplished even without any specific 
tailoring of the particles [16]. Therefore, in this work, drug delivery systems 
comprising RIF-loaded nano- and microparticles made from two biodegradable 
polymers (GluN-LLA and PLA) are presented as a potentially new strategy to 
treat tuberculosis.  
1.3. Background 
This section presents basic background material which will be relevant to more 
specific discussions in subsequent chapters. 
 
1.3.1. Particulate Drug Delivery Systems 
 
Generally, conventional drugs are low molecular weight substances capable of 
crossing body barriers and accessing numerous cell types and subcellular 
organelles. Although this aspect represents a desired feature for the treatment of 
diseases, it also implies an indiscriminate distribution of the drug to an 
uncontrollable extent of the body. As a consequence of this drug ‘dilution’ in the 
body, higher doses of the therapeutic agent are required for a satisfactory 
pharmacological response, which usually carry undesired side effects on the 
patient. Rapid renal clearance of drugs requires frequent administration, 
threatening, especially in long-term treatments, the compliance of the patients 
[17]. Compliance is crucial for curing tuberculosis. Standard multi-antibiotic 
11 
 
treatment results in systemic delivery of the drugs throughout the body; drugs are 
rapidly detoxified and/or excreted, and daily doses are required. RIF, INH and 
PYZ, first-line anti-tuberculosis drugs, are metabolized by the liver and induce 
hepatotoxicity. This adverse effect is of primary concern, because it often 
requires changes in the treatment [13,16]. 
 
Controlled-release drug delivery systems are designed to provide adequate 
doses of therapeutic agents for a relatively long period of time, to the proper 
location, in an effective manner to increase compliance and minimize side effects 
[18]. These systems employ devices that are capable of releasing drugs by 
reproducible and predictable kinetics. Biodegradable polymeric nano- and 
microparticles are among the most investigated types of devices as drug delivery 
vehicles. Some of their advantages are, (1) drug release rates can be tailored to 
the need of a specific application, (2) protection of the drug from degradation and 
clearance, especially proteins, with lower required doses, (3) improved patient 
comfort and compliance by decreasing the frequency of doses, for example, 
sometimes even from daily to weekly doses, and (4) localized, targeted delivery 
of the drug to minimize side effects [17–19]. Controlled-release particle 
formulations that maintain a constant level (zero-order release kinetics) of a drug 
for long periods of time i.e, effectively prolonging the therapeutic effect of one 
dose, is the ultimate long-term goal in developing the drug carrier systems 
presented in this dissertation. These formulations are often referred to as 
“sustained release”, or “prolonged release formulations” [20]. One critical concern 
with orally administering RIF is its bioavailability in the acidic environment of the 
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stomach. RIF displays decomposition rates between 8.5 to 50% in the 
corresponding gastric time for most treatment modalities in humans (~15 to 105 ± 
45 min) [21,22]. The entrapment of RIF inside ultrafine particles serves not only 
as a means to develop a slow-release reservoir system, but also as protection 
from degradation, which in principle solves the RIF bioavailability issue [7].   
 
1.3.1.1. Drug release mechanisms and mathematical modeling 
 
Several factors affect release rates in nano- and microparticles, such as mode of 
drug entrapment, polymer type and its molecular weight, copolymer 
compositions, polymer matrix-drug interactions, excipients, particle geometry, 
and physicochemical and biological properties of the active and carrier 
ingredients, among others [17,18,23,24]. Drugs can be encapsulated inside a 
“core” or reservoir surrounded by a thin polymer “shell”, or can be uniformly 
dispersed or dissolved in the polymer matrix. These two different drug 
entrapment modalities are usually defined by the type of particle being designed 
for, i.e., core-shell or solid particle. The polymer type and its molecular weight are 
governing elements affecting the mechanism by which the drug is released from 
the particles. These factors strongly influence particle characteristics like 
degradation rate, swellability and polymer matrix interaction with the drug [24]. In 
this dissertation, RIF was dissolved in GluN-LLA and PLA matrix, and four 
particulate drug delivery systems were produced. Drug release studies and 
mathematical modeling from this data are used to assess the relative importance 
of drug-matrix interactions.  
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Numerous mathematical models that predict polymer drug delivery behavior have 
been reported over the last few decades [25]. The classic Ritger and Peppas 
equation Mt/M∞ = kt
n  [26] is a simple exponential form that can be used to fit drug 
release kinetic data. In the equation, Mt/M∞ is the drug cumulative release 
percentage at time (t), k is the rate constant, and n is the so-called diffusional 
exponent. Both n and k are determined by the principles governing diffusion, 
degradation, relaxation, matrix-drug interaction, and geometry of the drug 
delivery system. Fickian-type diffusion of a drug for example, is driven by a 
chemical potential gradient. Relaxational release refers to systems possessing a 
swellable matrix, and is mostly hydrophilic polymers. In this particular case, the 
carrier’s polymer chains “relax” upon contact with water or biological fluids, and 
this facilitates drug delivery by increasing its mobility across the matrix.  
 
In the pharmaceutical field, data from drug release experiments are generally 
fitted to the Ritger and Peppas equation, and the obtained n value is used to 
propose a drug release mechanism [25]. For spherical particles, a pure Fickian 
diffusion controlled-release system is described by n=0.43, while n=0.85 is 
related to swelling-controlled drug delivery mechanism. Values of n between 
these two numbers represent drug release systems controlled by both diffusional 
mass transport, and chain relaxation. The case of n=0 correspond to a zero-order 
drug release process, and is related to systems displaying pure biodegradation-
controlled behavior, where drugs are strongly entrapped (e.g. covalently bonded) 
within the polymer matrix [27]. Values of n between 0 and 0.43 represent an 
overlap of drug-matrix interaction and diffusion mass transport mechanisms [27]. 
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Since Ritger and Peppas equation does not fit data well in cases where high 
degradation rates occur, other mathematical models may be adopted. 
Biodegradable polymers are widely used in the design of nano- and 
microparticles as controlled drug delivery systems. Polymer degradation routes 
can be divided into two different categories: bulk-eroding and surface-eroding 
degradable systems. Numerous mathematical models that apply to degradable 
systems can be found in the literature [19,28]. 
 
For the sake of illustration, one can picture a model solid nanoparticle having the 
drug uniformly dispersed in a degradable copolymer matrix, and the different 
possible mechanisms of controlled drug delivery systems. Case 1: the rate of 
degradation is slow enough for the particle to be taken as non-degradable during 
the release period, and the matrix does not either swell or presents no important 
interaction with the drug. This drug delivery system would probably be controlled 
by pure Fickian diffusion (n=0.43) [26]. Case 2: swellability effects in the polymer 
matrix are large enough that when water diffuses into the particle, polymer chains 
relax and drug is released by a swelling-controlled process (n=0.85) [29]. Case 3: 
very strong drug-matrix interactions or polymer-drug conjugates are formed. Drug 
release depends only on biodegradation or chemical erosion to free the drug 
from the particle (n=0).  These three situations represent the three extreme cases 
of drug delivery i.e., a process governed by one single phenomenon (diffusion, 
relaxation and degradation). Systems that are controlled by a combination of two 
or more phenomena are all too common, e.g. diffusion and relaxation coupling 
(0.43<n<0.85) [30]. Values of n between zero and 0.43 are generally taken as 
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indicative of diffusion and matrix-drug interaction mechanisms being present. 
Matrix-drug interactions are most likely responsible for strong delaying effects in 
observed drug release profiles. In this last case, the polymer matrix does not 
undergo swelling, and the carrier’s degradation rate is also not an important 
factor. 
 
In this dissertation, GluN-LLA nano- and microparticles particles have been 
produced, with the goal of functioning as controlled-release drug delivery 
systems. Since their biodegradation rates were relatively modest (see Chapter 
3), it was not considered to be an important factor in the modeling of the release 
process. Due to GluN-LLA particles containing a larger proportion of L-lactide 
molecular building blocks relative to their glucosamine core unit, this copolymer 
was a priori viewed as a good non-swelling system. Therefore, the Ritger and 
Peppas equation was viewed as a viable candidate to model the drug release 
profiles.  
 
Frequently, especially for prolonged release products, there are three basic 
stages in a time-release profile: (1) initial burst of drug release, taking place 
during the first few hours, followed by a (2) slow diffusion-controlled release, and 
finally, a (3) phase where drug is released faster as a consequence of 
degradation start playing a pivotal role. Burst release is usually linked to drug 
diffusion from the outermost layers of the particles. In some cases, degradation 
can be controlled to a good extent by varying the ratio of the monomeric building 
blocks in copolymers. For example, poly(lactic-co-glycolic) (PLGA) degradation 
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rates can be increased by having higher glycolic acid contents [20]. Despite the 
observed differences between drug release phases one and two (chapter 3), RIF 
release profiles from GluN-LLA and PLA particulate systems showed no phase 
three during the observation period (~14 days). This also suggests a slow 
degradation rate.     
 
1.3.1.2.  Drug Delivery Approaches for Tuberculosis Treatment 
 
As mentioned in Section 1.2, tuberculosis chemotherapy requires the 
administration of a multi-drug regimen over a long period of time. Low patient 
compliance is the main reason for treatment failure, which in turn frequently 
causes MDR tuberculosis and/or patient death. In order to improve compliance, 
minimize toxicity and to increment RIF bioavailability in tuberculosis treatment, 
efforts have been made to develop drug delivery systems composed of nano- 
and microparticles. 
 
Various drug carriers derived or purified from natural sources such as chitosan 
[31], alginate [32,33], gelatin [34], fatty acids (Pheroid technology) [35] and 
synthetic encapsulants, such as poly(lactide-co-glycolide) (PLGA) and poly-D,L-
lactide (PDLLA) have been used in anti-tuberculosis drug encapsulation. RIF is 
one of the first-line antibiotics being used in treatments of tuberculosis, and is 
usually employed when investigating new particulate systems. A review of the 
recent literature on RIF controlled release systems reveals that the most popular 
drug carriers still belong to PLGA family [12,36–47]. For studying a subcutaneous 
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injection approach, Dutt et al. [44] produced PLGA microparticles containing RIF 
and INH by the double emulsion evaporation technique and particles size was 
11.75 µm and 11.64 µm respectively. The particles were administered in a single 
dose subcutaneously to mice; the microparticles sustained a therapeutic release 
of the drugs for 7 and 6 weeks for INH and RIF respectively. As an observation, 
authors showed that particles with diameter > 10 µm remained at the site of 
injection, forming a depot where drugs were released via diffusion processes. 
Such a depot can release drugs over several weeks, while the same dose of free 
drugs were present in vivo only for 24 hours. It needs to be indicated however, 
that subcutaneous and intravenous routes of administration involve injections, 
which in turn lead to additional patient pain and discomfort. This tends to favor 
the development of oral and inhalation drug delivery systems as being more 
convenient to patients and as a natural result, more research has been reported 
for the oral and inhalation drug administration routes. 
 
As an oral formulation strategy, Ain et al. [45] used a double emulsion technique 
to encapsulate RIF, INH and PYZ in PLGA microparticles with a size range 
distribution between 1.1-2.2 µm. These particles were administrated orally in 
mice, and drug concentrations achieved via use of microparticles were compared 
with those resulting from use of the free drug. In all cases, encapsulated drugs 
remained present in circulation for up to 72 hrs after dosage, while administration 
of free drugs led to their elimination within 24 hrs. Pandey et al. [47] prepared 
RIF, INH, PYZ loaded PLGA nanoparticles by the multiple emulsion technique 
obtaining a particle size range between 186-290 nm, with a drug encapsulation 
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efficiency of 56.9±2.7 %. Drug levels in plasma reached therapeutic values for 6-
8 days and for up to 11 days in the lungs with a single dose administration to 
guinea pigs. Even though use of drug-loaded microparticles leads to lower doses 
and lower administration frequency via the oral route than when the free drugs 
are administered, first-pass metabolism is still a concern. This phenomenon (also 
known as first-pass elimination or presystemic metabolism) refers to the drug 
fraction that is metabolized after its administration, and before it is effectively 
utilized at the desired therapeutic site. The primary organ involved in first-pass 
metabolism of an orally administered drug is the liver, other areas with less 
impact on first-pass metabolism are the gastrointestinal tract, blood, vascular 
endothelium and lungs [48]. 
 
In the case of pulmonary drug delivery, inhalation therapy has the added 
advantage of being capable of releasing the anti-tuberculosis drugs right at the 
main site of infection, where alveolar macrophages harbor M. tuberculosis 
bacteria inside the phagosomes. In addition, inhalation therapy has the inherent 
benefit of chiefly bypassing first-pass metabolism, thereby allowing elevated local 
concentrations of the drug where it is most needed, and without requiring high 
drug concentrations in circulation. This, in turn, reduces systemic toxicity risks. 
Via the inhalation route, it is also possible to achieve systemic therapeutic 
concentration of the drugs [7,49]. This is important in that tuberculosis is a 
systemic disease that primary affects the lugs, but can also affect other areas as 
well such as the liver, kidney and spleens. There are a considerable number of 
publications in the open literature that propose formulation of anti-tubercular 
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drugs into nano- and microparticles for pulmonary delivery. In spite of the fact 
that first-line drugs are the ones that are predominantly used, other second- and 
third-line anti-tubercular drugs have been investigated [7,49,50].  RIF alone has 
been encapsulated in PLGA microparticles mostly by means of two techniques: 
double emulsion [46,51,52] and spray drying [12,52,53]. RIF has been also 
encapsulated in combination with other first-line anti-tuberculosis antibiotics, 
especially with INH and PYZ [47,51,54]. Table 1 shows what are believed to be 
the most relevant published research in RIF-loaded microparticles made out of 
synthetic polymers for pulmonary delivery treatment of tuberculosis. As it can be 
observed, values for drug loading (DL) capacity vary between 10-30% for PLGA 
and 8-16% and for PLA microparticles. Other natural materials such as chitosan 
[31], alginate [32], and gelatin [34] were also employed to encapsulate RIF, and 
showed DL of 8.9-46.3%, 25-37%, and 42%, respectively. In this dissertation, 
stable RIF-loaded particles presenting DL of 50% were produced by the 
electrospray technique. This superior characteristic of GluN-LLA systems is 
attributed to the fabrication method (next section), and the physicochemical 
properties of the polymer that promote high drug-polymer interactions (Chapter 
3).               
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Table 1.1 – Rifampicin -loaded particles made of synthetic polymers for 
pulmonary delivery treatment of tuberculosis. Particle diameter (Pd), drug loading 
(DL)  
Ref. 
Manufacturing 
method 
Pd 
(µm) 
Carrier 
DL 
(%) 
Drug release and comments 
[52] 
Emulsion 
3.45-
6.84 
PLGA 20 In vitro release 34% in 24hrs 
Spray drying 2.76 PLGA 30 In vitro release 74% in 24hrs 
[12] Spray drying 2.87 PLGA 30 In vitro release 52% in 24hrs 
 
[42] 
Spray drying 
1.5 
and 
3.5 
PLGA 10 
Phagocytosis dependency on 
particle size: 80% uptake 3.5 
µm microparticles.  
 
[41] 
Emulsion 2.84 PLGA 10 
Drug release accelerated by 
pulmonary surfactant (release 
50-90% in 24 hrs) 
 
[55] 
Supercritical 
anti-solvent 
process 
3.29 PLA 8-16 
Optimization of fabrication 
method conditions. Release 
30-100 % in 24 hrs) 
 
 
[53] 
Spray drying 2.76 PLGA - 
Intracellular RIF from particles 
containing 0.25 and 2.5 μg 
RIF/mL were 2 and 10 times 
higher than 5 μg/mL of free 
RIF – ~50 % intracellular 
killing after 7 days 
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1.3.1.3.  Electrohydrodynamics as a Tool for Fabricating Drug Delivery 
Carriers  
 
Over the past few decades, there has been a growing interest in developing 
biodegradable nano- and microparticles as drug delivery systems. There are 
several methods for making ultrafine particles, such as emulsification-
evaporation, salting-out/emulsification, nanoprecipitation, ionic gelation, 
coacervation, spray-drying and electrospray, among others [56–58]. As it can be 
deduced from Table 1.1, for pulmonary delivery of RIF, the emulsion/solvent 
evaporation and spray-drying methods are the ones that are most frequently 
used.  
 
Solvent evaporation and emulsion-based methods are commonly used to 
prepare ultrafine particles, especially at lab scale. The emulsification/solvent 
evaporation technique involves emulsification of a dispersed phase in which the 
polymeric matrix and the drug have been dissolved or dispersed. The two phases 
are emulsified at high sheer rates, until the solvent evaporates and particles are 
formed [50]. RIF-loaded PLGA microparticles of diameters in the 3.5 to 6.5 µm 
range for pulmonary delivery were prepared using this method by O’Hara and 
Hickey [52]. Methylene chloride and polyvinyl alcohol (PVA) were used as 
dispersant and emulsifier, respectively. The two phases were mixed at 5000 rpm 
for 45 min, and particles were collected by filtration. However, emulsion-based 
methods possess a number of important disadvantages have limited their 
application. Large-scale production poses great technological difficulties, and is 
cost-prohibitive. Particle size distributions are usually broad, and standard 
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deviations of 50% are not uncommon. This, in turn, makes consistent drug 
release profiles difficult to obtain. Drug exposure to organic solvents, high 
temperatures and high shear stresses could potentially decrease, or in some 
cases eliminate drug viability, especially with delicate biomacromolecules. In 
addition, toxic compounds such as some of the additives and/or surfactants used 
in this process, require time-consuming steps for their removal [18].  
 
The spray-drying method has grown in popularity to manufacture respirable 
particles due to the variety of materials that can be employed with it, and the 
range of sizes (microparticles) that can be obtained. This technique is a one-step 
process that produces particles from the atomization of a liquid feed. The 
droplets from the spray are dried to form solid particles. As shown in Table 1.1, 
RIF-loaded PLGA microparticles have been successfully produced by this 
technique [50,59]. However, this particle manufacturing process requires high 
capital costs, and bulky equipment that is expensive to maintain. Process scale- 
is still an important challenge with this method. This is rooted in the low thermal 
efficiency of the system i.e., the large volume of heated air with low or no contact 
with particles [59]. 
 
Electrospray, one of the two popular electrohydrodynamic (EHD) techniques, is a 
facile, inexpensive fabrication method that uses an electric field gradient to 
create solid or hollow particles. EHD principles, modes of operation, and 
instruments for small-scale production are well-established and well described in 
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the literature (see figure 1.3) [57,58,60–63]. The basic, lab-scale ES system 
consists of (1) a high voltage power supply, (2) a spinneret, and (3) a grounded 
collector plate. Electrical forces counter the effect of surface tension of the 
polymer solution extruded from the spinneret. The net result is the formation of a 
quasi-conical meniscus at the exit orifice. Typically, from the Taylor cone’s apex 
an electrified liquid jet is ejected and breaks down into droplets. Particles are 
generally formed depending on where, during the “time of flight” of the electrified 
droplets to the collector electrode, solidification due to solvent evaporation occurs 
[57,58,60–63]. 
 
 
Figure 1.3 - Basic electrospray apparatus 
 
 
Chakraborty et al. discussed the physics involving electrospray [58]. Important 
phenomena governing electrospray are electrodynamic, gravity, inertia, and drag 
forces. Electrodynamic forces are proportional to the induced electric field on the 
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charged nozzle and flying droplets. Drag forces depend on the jet velocity, and 
the viscosity of the gas surrounding the nozzle. The following scaling relation has 
been developed: 
𝑑 = 𝛼 
𝑄𝑎𝑄𝜀0
𝑎𝜀𝜌1
𝑎𝜌
𝜎1
𝑎𝜎𝛾1
𝑎𝛾 , (equation 1.1) 
 
Where, d is droplet diameter, Q is the volume flow rate, ε0 is the permittivity of 
free space, ρ1 is liquid density, σ1 is liquid surface tension, γ1 is liquid bulk 
conductivity, and α is a coefficient that depends on liquid permittivity. These and 
other characteristic parameters and coefficients have been studied by different 
authors. Typical values are in table 1.2: 
 
Table 1.2. Coefficient for equation 1.1 to determine droplet size 
Authors aQ aε aρ aσ aγ 
Fernandez de la Mora and Loscertales [64] 1/3 1/3 0 0 1/3 
Gañán Calvo [65]  and Gañan Calvo et al. [66]  ½ 1/6 1/6 1/6 1/6 
Hartman et al. [67] ½ 1/6 1/6 1/6 1/6 
 
Two principal modes of electrospray operation for making ultrafine particles have 
become popular over the last two decades: monoaxial and coaxial fluid delivery. 
Monoaxial electrospray utilizes a one-nozzle, one-liquid delivery arrangement, 
and creates solid particles with matrix-encapsulated drugs. Coaxial electrospray 
uses an emitter based on two coaxial nozzles to make core-shell particles. 
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Monoaxial electrospray was used in this dissertation to produce RIF-loaded solid 
GluN-LLA and PLA nano- and microparticles. In this case, RIF was embedded in 
the particles through dissolving it in the polymer solution precursor.      
 
The electrospray method has several advantages in the preparation of nano- and 
microparticles over other methods. Residual charges on the particles and drying 
effect of EHD “atomization” assure little or no aggregation on solvent 
evaporation. The absence of high-shear forces such as those present in stirring 
or sonication protects drugs with fragile molecular structures. Besides high 
loading levels and high encapsulation efficiency, electrospray achieves uniform 
dispersion of the drug in the polymeric matrix if so desired. Also, EHD methods 
are easy operable at a laboratory scale [58].   
 
Thus, among the various ultrafine particle preparation methods currently 
available [56–58], electrohydrodynamic atomization (EHDA) stands out for its 
simplicity and general applicability [57,58]. The EHDA production of particles from 
many synthetic and naturally occurring polymeric systems as drug carriers has 
been demonstrated in the past [58,61,68]. It has also been shown recently that 
both particle size and morphology can be controlled in a relatively simple manner 
with this method [69]. 
 
Papers on EHDA processing of polylactides (PLAs) for this particular application 
are scarce [70], and very few studies reporting on the preparation of MP made 
from PLA polymers loaded with RIF using spray drying techniques [55,71,72]. 
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Bain and co-workers [71] produced RIF loaded PDLLA microparticles from a 
series of mixtures of low (2 kDa) and modestly low (9 kDa) molecular weights 
(MWs). The RIF release rates were strongly affected by relatively small changes 
in the mixture composition, and increased with increasing content of the low MW 
(LMW) fraction. Celikkaya and co-workers [72] prepared a series of 
microparticles using PDLLA with MWs in the 9,7-23 kDa range, obtaining a 
maximum drug loading of only 10%. Moreover, a rather “permanent” RIF 
entrapment within the polymer matrix occurred. This, coupled with the slow 
PDLLA degradation kinetics, resulted in only a 20-30% release of the initial drug 
payload. Similarly, Coowanitwong and collaborators [73] found incomplete RIF 
release during the first 24 hours from microparticles prepared using HMW PLA 
(75-125 kDa) and PLGA (40-65 kDa). It is worth mentioning that among the 
polylactide polymer family members, PDLLA is favored for drug delivery 
applications owing to its disordered chain structure, which in turn translates into a 
purely amorphous material [43]. 
1.3.1.4. Drug Delivery system: Cost analysis  
 
An efficient delivery vehicle should have the potential to reduce dosages and 
side effects related to unintended dispersion of the drug through the body. 
Delivering the correct dosage to the proper location is important not just from 
safety, convenience and efficacy standpoints, but also from a cost-cutting 
perspective [74] . The implementation of RIF-loaded GluN-LLA ultrafine particles 
as drug delivery systems for the treatment of tuberculosis would potentially 
decrease the conventional therapy costs by reducing the amount of drug used 
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during the treatment. As mentioned before, the RIF-loaded particles presented in 
this dissertation are eventually intended to be administrated by the inhalation 
route, and thus to effectively target the M. tuberculosis harboring inside the 
alveolar macrophages. The immediate significance of this targeting is two-fold: to 
achieve drug dose reduction, and to potentially decrease the overall treatment 
time. A reduction in the amount of drug used for adequate treatment would 
translate into a substantial decrease in costs when compared to conventional 
treatment modalities. In addition to reduction in the occurrence and frequency of 
side effects, the fact that GluN-LLA particles deliver RIF for a long period of time 
(~14 days, chapter 3) would decrease the frequency of drug administration, and 
as a consequence, patients would likely be more compliant to treatment. High 
levels of adherence to treatment will also stop the development of MDR 
tuberculosis (and decrease the use more expensive and toxic drugs), and 
ultimately reduce healthcare costs.  
 
Even when GluN-LLA synthesis and particle processing are cost-effective and 
easily scalable when compared with other techniques (section 1.3.1.3), the final 
drug delivery product, which is envisioned as dry powder inhaler, will eventually 
cost more than pure RIF on a weight of drug basis. However, the cost cutting 
factors in this case will be efficacy enhancements, patience compliance and 
shorter treatment duration [75]. In this regard Owens et al. published an 
evaluation of the cost-effectiveness of a novel first-line treatment with 
hypothetical regimens of equal efficacy, higher cost, and shorter duration than the 
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conventional 6 months treatment. In their study, these authors conclude that the 
more novel treatment approach effectively reduced treatment costs.  
 
This doctoral dissertation proposes a pulmonary RIF delivery system capable to 
cure tuberculosis and effectively reduce the cost of treatment. This hypothesis 
would ultimately have to be tested by a comprehensive cost-effectiveness study. 
1.3.2. Glucosamine L-lactide (GluN-LLA) 
   
GluN-LLA, a new biocompatible oligomer is produced by a ‘one-spot’ synthesis 
route, where L-lactide chains are grown onto glucosamine molecules via –OH 
groups. This polymer and the production method were designed and first 
characterized by Skotak and Larsen [1] at the University of Nebraska – Lincoln in 
2010. These authors thoroughly characterized this polymer system via 1H and 
13C nuclear magnetic resonance (NMR), Fourier transform infrared (FTIR), and 
UV-visible spectroscopies, electrospray ionization mass spectrometry (ESI-MS), 
gel permeation chromatography (GPC), and differential scanning calorimetry 
(DSC). Conveniently, this polymerization method does not employ the 
conventional organometallic tin catalyst for the lactone ring-opening 
polymerization process, which eliminates the presence of cytotoxic impurities in 
the product. The synthesis of L-lactide grafted chitosan [2] was also successfully 
achieved by using this methodology, which demonstrates the simplicity and 
flexibility for grafting lactone chains onto simple aminosugars and sugar rings.   
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GluN-LLA (figure 1.2) is a low molecular weight star-shaped biocompatible and 
biodegradable polymer. By controlling the initial LLA-to-core molecule molar 
ratios it is possible to control the length of the lactide substituents, and 
consequently this GluN-LLA holds the capability of having a tunable 
hydrophobicity-hydrophilicity balance. In this dissertation, GluN-LLA 1:32 with a 
degree of substitution of 3.8/4 and lactate side length of ~11 monomers was used 
to produce RIF-loaded and drug-free nano- and microparticles (Table 1 in ref [1]).  
 
The fact that the building blocks of two of the most well-known biocompatible 
polymers (chitosan and PLA) have been used to produce one LMW co-polymer, 
a priori positions GluN-LLA as a potential material for biomedical applications. 
Moreover, the hypotheses of biocompatibility and biodegradability are tested in 
this dissertation. This thesis is thus the first documented implementation of a 
GluN-LLA oligomer as drug delivery system in particular, and biomedical 
applications in general. In this work, biocompatibility of the GluN-LLA nano- and 
microparticles is assessed via cell viability in Chapter 3.   
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Figure 1.2. Glucosamine-L-lactide oligomer 
   
1.3.3. Antimicrobial Susceptibility Test 
 
Antimicrobial susceptibility testing is important to determine susceptibility of 
species that are considered clinically significant in antimicrobial agents, or to 
detect resistance in individual bacterial isolates. The Clinical and Laboratory 
Standards Institute (CLSI) develops and provides standardized methods to 
perform antimicrobial susceptibility tests for several groups of bacteria. For 
instance, CLSI recommends the standard broth microdilution method for M. 
Smegmatis, thesis’s tuberculosis-model bacteria.      
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The broth microdilution method is based in the ability of the isolate (bacteria 
suspension) to grow in broth containing a single antibiotic concentration. The 
critical minimum concentration of an antimicrobial agent that prevents bacteria 
growth represents the minimum inhibitory concentration (MIC) [76,77]. Briefly, 
known quantity of bacteria is exposed to specified concentrations of one 
antibiotic. Following overnight incubation, visible bacterial growth (as evidenced 
by turbidity) is examined, and MIC is determined [78].  Using these standards, 
the minimum bactericidal concentration (MBC), which is the lowest concentration 
of the drug that kills ~99.9% of bacteria, can be determined.   
1.4. Approach: Ultrafine Particles as Drug Delivery System 
 
Many treatment strategies to increase the dose of antibiotics inside alveolar 
macrophages have been devised in recent years. Among them, drug 
encapsulation in liposomes, nanoparticles (NP) or microparticles (MP) that can 
undergo endocytosis by alveolar macrophages holds significant promise 
[15,40,53,79,80]. Some advantages of using encapsulated drugs for infection 
treatments are shortened treatment time, reduced dose frequency, and lower 
doses [81]. In addition, by using drug-loaded particle systems the intracellular 
delivery and bactericidal activity of antibiotics have shown significant 
improvement when compared to that of the free drug [53,82–84].  
 
Particles can be delivered by several administration routes, including inhalation. 
One important benefit of the inhalation route for tuberculosis treatment is that the 
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drug would be released to the desired site, directly to the alveolar macrophages 
where M. tuberculosis is harboring. This would facilitate a faster antimicrobial 
action, and help to reduce the long period of the current treatment. The main 
advantage of the inhalation route resides in the fact that it eludes first-pass 
metabolism, thereby reducing side effects, lowering drug dose, and more 
efficiently targeting alveolar macrophages [6,85]. High intake of RIF could 
present serious hepatic side effects, such as hepatotoxicity and renal failure [13]. 
Thus, in this work, the development of a particulate system able to efficiently 
deliver the right drug amounts over time to alveolar macrophages is sought. The 
RIF-loaded particulate system is envisioned as a pulmonary delivery of RIF. 
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2.1. Materials 
 
Rifampicin (RIF, >97% HPLC), D-(+)-Glucosamine hydrochloride (GluN-HCl, min. 
99%), ethyl acetate (99.8%) and methanesulfonic acid (>99.5%) were from 
Sigma-Aldrich, and ethanol (>99.5%) was received from McCormick Distilling 
Co., Inc.. High molecular weight poly-L-lactide (HMW PLA, NatureWorks Ingeo™ 
8302D) with Mn = 123 kDa and polydispersity (PDI) 1.75 (GPC)) was purchased 
from Jamplast, Inc. The L-lactide (LLA, 98%, Alfa) was re-crystallized from 
toluene, vacuum-filtered in an argon atmosphere, vacuum-dried, and stored in a 
desiccator. All the other chemicals and reagents were purchased from Sigma-
Aldrich except where indicated. The low molecular weight poly-L-lactide and 
GluN-LLA polymer synthesis is described in the next section.  
 
2.1.1 Polymer Synthesis  
 
Low molecular weight poly-L-lactide (LMW PLA, Mn = 2,500 Da, PDI=1.4 (GPC)) 
was synthesized according to a procedure published elsewhere [86]. The GluN-
LLA (Mn
 = 3,100 Da (NMR), PDI = 1.47 (GPC)) with average side-chain length of 
11 monomeric L-lactide units, was prepared according to a procedure reported 
earlier [1,2]. Briefly, 10 mL of methanesulfonic acid were transferred into a 50 mL 
flask under argon atmosphere and placed in an oil bath kept at 40°C. 
Subsequently, 3.5 mmol of GluN-HCl was added and stirred until 
homogenization. Then, the L-lactide was added to the reaction mixture, and the 
flask was flushed with argon for 10 minutes to remove the liberated gaseous HCl. 
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Polymerization of L-lactide occurred for four hours, and the reacting mixture was 
afterwards quenched with an acid-base neutralization solution, as described 
elsewhere [2]. Vacuum filtration and vacuum drying overnight at the ambient 
temperature were carried out to isolate and dry the product. Samples were stored 
in a desiccator until use. 
2.2. Particle Preparation and Characterization 
 
2.2.1 Particle Preparation 
 
Polymeric nanoparticles were prepared from a 5% (w/v) GluN-LLA or LMW PLA, 
while microparticles were prepared from a 20% (w/v) GluN-LLA or 1% (w/v) 
HMW PLA. The preparation of polymeric precursor solutions was done by 
dissolving the corresponding polymers into ethyl acetate.  These solutions were 
processed into four different sets of particles using a conventional single-nozzle 
EHDA setup. The resulting particles were labeled as SMP-GluN-LLA, SMP-LLA 
and MP-GluN-LLA, MP-LLA, respectively. For the preparation of RIF-loaded 
particles, three different drug loadings were used: 10, 20 and 50 wt%, which 
correspond to RIF-to-polymer mass ratios of 1:10, 1:5 and 1:1, respectively, 
being the 1:5 and 1:1 ratios the most studied in the present thesis. The precursor 
solution was loaded into a Hamilton series 1000 gastight syringe (model 1001, 1 
mL), then a 19 gauge, blunt needle was attached to the syringe (to serve as the 
EHDA nozzle). Subsequently, the syringe was attached to a digital syringe pump 
(Cole-Parmer 74900-00, Vernon Hills, IL). Voltage differences in the range of 5-
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15 kV, (Gamma High Voltage Research ES30P-5W/PRG, Ormond Beach, FL) 
and a nozzle-to-collector distance of 10 cm were used in the course of a typical 
experiment. Various flow rates in the range of 0.2-0.5 mL h-1 were tested to find 
optimal processing conditions in order to make particles with narrow diameter 
distributions. The particles were deposited onto an aluminum foil collector tightly 
wrapped around 15 cm OD circular copper disk. The temperature and relative 
humidity during the collection of particles were approximately 24ºC and 45%, 
respectively. The collection time was limited to 10 minutes (optimization phase) 
or extended up to a few days to collect amounts of particles suitable for further 
studies. 
 
2.2.2 Size and Morphology 
 
Particle size and morphology were assessed via scanning electron microscopy 
(SEM), using a Hitachi S-3000N microscope with an accelerating voltage of 15 
kV and working distance of approximately 10 mm. Coating with metallic gold for 2 
minutes before SEM characterization was used to enhance the contrast of non-
conducting samples. The electrical current inside the chamber of the Technics 
Hummer II sputter coater was kept constant (10 mA). Statistical analysis of 
particle size measurements from SEM images was performed on sets of at least 
250 counts within each specimen.  
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2.2.3. Drug Release Studies 
 
Drug release studies were performed under “perfect sink” conditions [26]. Briefly, 
a mass equal to 50 mg of RIF-loaded particles was dispersed in 5 mL of 
phosphate buffered saline (PBS) (n=3) (pH = 7.4) supplemented with 0.02% of 
ascorbic acid as an antioxidant [40], the vials were kept in a thermostat/shaker at 
37.0±0.1°C in the dark. Samples of 200 µl were extracted from each vial every 
hour for the first 8 hours, and then every 24 hours. The total volume was kept 
constant by replacing the extracted sample volume with 200 µl of fresh PBS. RIF 
content was measured with a Beckman DU-640 spectrophotometer in the 250-
550 nm wavelength range. In the past, the RIF release kinetics had been 
evaluated at the isosbestic point of the drug, and through its quinone degradation 
product (330 nm) [38,71]. Absorbance values at 310 nm were used to calculate 
the concentration of RIF in the absence of drug oxidation, which was prevented 
by addition of ascorbic acid and a lack of sample exposure to light. 
 
2.2.4 Particle Degradation 
 
Polymer degradation studies were performed using a modified PBS (pH = 7.4) 
solution: water was replaced with deuterated water to facilitate NMR analysis of 
the released L-lactic acid. First, the pH of the PBS stock solution was adjusted to 
7.4 with 1 M HCl, then water was evaporated and the remaining solid was dried 
under vacuum. Then, the dry PBS powder was dissolved in deuterated water 
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(D2O, 99.8 atom % D, Cambridge Isotope Laboratories) for further use. Solid 
polymeric particles (50 mg) were dispersed in 5.0 mL of deuterated PBS and the 
suspension was kept in the dark at 37 °C while shaking it. For NMR analysis, 0.5 
mL aliquots were drawn every 24 hours and 1H NMR spectra were recorded on a 
Bruker Avance 500 NMR spectrometer at 500.13 MHz to track the release of L-
lactic acid. Following analysis, samples were poured back into their respective 
particle suspensions. These studies were done in triplicate for all tested particle 
types, and for 14 consecutive days. 
 
2.2.5 Drug Encapsulation Efficiency 
 
Approximately 40-50 mg of RIF loaded particles were treated with 5 mL of 
anhydrous ethanol for 10 minutes (L-lactide polymers are not soluble in this 
solvent, RIF solubility in ethanol is roughly 10 mg/mL). The suspension was then 
centrifuged, the supernatant transferred to a 30 mL beaker and subsequently 
diluted to 15 mL. UV-Vis spectra of RIF in ethanol were recorded in the 250-550 
nm range, and concentrations were calculated based on the absorption peak at 
306 nm. 
 
The drug content entrapped within the particles was analyzed with 1H NMR 
spectroscopy, using deuterated chloroform (CDCl3, 99.8 atom % D, Sigma-
Aldrich) as solvent. Characteristic signals of methyl groups of RIF (1.04, 0.89 and 
0.62 ppm) and polymer matrices (1.60 ppm) were compared and used to 
40 
 
calculate the drug-to-polymer ratio. Particles that were not treated with ethanol 
were used as reference. 
 
2.2.6. Thermal Properties of RIF Loaded Particles 
 
Differential Scanning Calorimetry (DSC) runs were performed on Q100 machine 
(TA Instruments, New Castle, USA), calibrated for temperature and heat flow 
using indium (melting point 156.6 °C and ΔHm, 28.45 J/g, respectively). Two 
analytical runs (to confirm repeatability) were performed on each sample at a 
heating rate of 10°C/min., by ramping temperature from 0 to 300°C, and the 
sample compartment was flushed with dry nitrogen flowing at 25 mL/min. An 
empty hermetic aluminum pan was used as a reference. 
 
2.3 Data Fitting and Statistical Analysis 
 
Data fitting of temporal RIF release profiles was performed using non-linear 
curve fitting built-in module of the Origin® 9.0 software. Typically, 60% of the data 
points were used and fitted to the Korsmeyer-Peppas equation (as required by 
the model) [26]. Statistical evaluation was performed using ANOVA test with p-
values below 0.05 and 0.01 considered as significant. 
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2.4 Evaluation of Particle Effects on Bacteria 
 
2.4.1 Bacterial Strain 
 
M. smegmatis ATCC 607 was purchased from Hardy Diagnostics (Santa Maria, 
CA), and cultured at 37ºC and 150 rpm in Difco Middlebrook 7H9 (BD 
Diagnostics, Sparks, MD) medium supplemented with 0.5% (v/v) glycerol and 
0.05% Tween 80 to prevent clumping, 10 µg/mL cycloheximide to prevent fungal 
contamination, 50 µg/mL carbenicillin to prevent other bacterial contamination, 
and ADS (0.5% bovine serum albumin, 0.01 M dextrose and 0.015 M NaCl). For 
each experiment, a fresh overnight culture was prepared with a terminal OD600 
reading less than 0.4. 
 
2.4.2 Particle Toxicity on M. Smegmatis 
 
Three million colony forming units (cfu) of freshly prepared mycobacteria were 
inoculated in 10 mL of 7H9 complete medium for 1 hour at 37ºC before the 
addition of different amounts of particles (0, 300, 600 and 1,200 µg/mL). The 
cultures were maintained in the oven at 37ºC with continuous shaking at 150 rpm 
for 24 hours, and then 10 µL of culture was inoculated onto 7H10 agar plates 
(7H10 agar supplemented with the same ingredients as 7H9 complete medium 
without Tween 80) without spreading out, and incubated at 37°C for 3 days to 
produce visible colonies. Mycobacteria in 7H9 complete medium without particles 
were considered the particle toxicity control. Pictures of agar plates were taken 
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with a digital camera (24 Mega Pixels resolution); areas of the colonies formed 
were quantified by ImageJ software. 
 
2.4.3 Determination of Minimum Inhibitory Concentration (MIC) 
 
The MIC of free RIF and RIF-loaded particles for M. smegmatis were determined 
by standard macrobroth dilution techniques recommended by the Clinical and 
Laboratory Standard Institute (CLSI). Briefly, a series of dilutions of RIF-free (0, 
1, 2, 4, 8, 16, 32, 64, 128, 256, 512 µg/mL) and encapsulated RIF particles 
(according to 1:5 RIF-to-polymer mass ratio, 0, 5, 10, 20, 40, 80, 160, 320, 640, 
1280, 2560 µg of loaded particles/mL, and 1:1 ratio 0, 2, 4, 8, 16, 32, 64, 128, 
256, 512, 1024 µg of loaded particles/mL) in 7H9 medium were prepared. 
Bacterial suspensions were then added to each tube to make final inocula of 3 x 
105 cfu/mL; the lowest concentrations in antibiotic formulations that inhibited the 
visible bacterial growth after 24 hours were assigned as MIC using McFarland 
turbidity standard value of 0.5 as reference. 10 µL of culture from each tube was 
taken and then placed onto a 7H10 agar plate without spreading it out. The 
plates were cultured at 37oC for 3 days before the colonies were analysed.  
Minimum bactericidal concentration (MBC) was defined as the smallest 
concentration which kills at least 99.9% of bacterial population compared with 
those in control vials. 
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2.5 Evaluation of Particle Loading Effects on Macrophages 
 
2.5.1 Cell Line 
 
Mouse macrophage cell line J774A.1 was purchased from ATCC (Manassas, 
VA). The cells were grown in Dubelco’s modified eagle’s medium (DMEM, Global 
Cell Solutions, Charlottesville, VA) supplemented with 10% fetal bovine serum 
(FBS, PAA Lab, Westborough, MA) and antibiotics containing 100 units/mL 
penicillin, 100 µg/mL streptomycin and 250 ng/mL amphotericin B (Lonza, 
Walkersville, MD) at 37oC and 5% CO2 in a humidified incubator. 
 
2.5.2 Cytotoxicity of particles on macrophage cells 
 
WST-8 assay (Dojindo Molecular Technologies, Inc) was performed per 
manufacturer’s instructions. In brief, J774A.1 macrophages were seeded in 96-
well plates at a density of 1 x 104 cells/well, and incubated with SMP-GluN-LLA, 
MP-GluN-LLA, SMP-LLA, and MP-LLA (0 (control), 30, 60, 120 and 240 µg/mL) 
for 3 days at 37°C  in humidified atmosphere (90% humidity), 5% CO2. WST-8 
reagent solution (10 μL) was added to each well without changing medium, and 
the plates were incubated for 1 hour prior to OD450 measurement with a BioTek 
Elx800 microplate reader. Viability of J774A.1 cells was determined from the 
absorbance of WST-8 in the cell suspension and sample without particle 
exposure was taken as 100% viability. 
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2.5.3 Particle Uptake, and Intracellular Localization by Confocal Microscopy 
 
To determine the internalization of particles into macrophages, 4 x 105 cells were 
seeded in 35mm glass bottom dishes (MatTek, Ashland, MA) and incubated for 
48 hours with 120 µg/mL particles labelled with 1 % poly-caprolactone-
fluorescein conjugate (PCL-fluorescein, Advanced Polymer Inc, Carlstadt, NJ).  
For these experiments, 1 % w/w PCL-fluorescein/polymer was added to the 
GluN-LLA or PLA solution before particle fabrication. Subsequently, the cells 
were stained with 100 nM of MitoTracker® or LysoTracker® (Invitrogen, 
Carlsbad, CA) in serum-free and phenol red-free DMEM for 10 minutes. 
CellMask™ plasma membrane staining (Invitrogen) was also performed to 
confirm the particle internalization. Finally, cells were washed and visualized with 
a confocal microscope (Olympus FV500-IX 81). 
 
2.5.4 Intracellular Killing of M. Smegmatis 
 
To examine the effects of RIF loaded particles on killing efficiency of M. 
smegmatis in macrophages, 105 cells per well were seeded in 24-well plates and 
allowed to grow for 24 hours before infection. After washing with antibiotics-free 
medium twice, 20 multiplicity of infection (MOI: ratio of bacteria/cells) of fresh 
growing M. smegmatis was used to infect the cells for 1 hour and then 
extracellular bacteria were killed by the addition of gentamicin (20 µg/mL). Free 
(30 µg/mL), or RIF loaded particles (60 µg/mL, according to 1:1 RIF-to-polymer 
mass ratio), was then loaded into the cell culture with growing medium without 
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antibiotics. After the incubation period, cells were washed and lysed with water 
and intracellular survival was estimated by plating serially diluted cultures on 
7H10 plates. Pictures of agar plates were taken with a digital camera (24 MP 
resolution), and the colonies were counted after 3 days with ImageJ software. To 
determine the relative population of surviving cells after infection, macrophages 
were stained with the Live/Dead viability kit (Invitrogen, 4 µM EthD-1 and 2 µM 
Calcein AM) before lysed. After 10 minutes of incubation with dyes, cells were 
examined with VWR Vistavision Inverted Epifluorescence microscope attaching 
to a LissView Imaging system. Live cells were counted with ImageJ software.  
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3.1. Particle Fabrication: Optimization of Processing Conditions 
 
The electrospray technique was used to prepare four sets of particles composed 
of two different polymeric materials, GluN-LLA and PLA. These groups of 
particles were labeled as SMP-GluN-LLA, MP-GluN-LLA, SMP-LLA, and MP-
LLA. In order to determine the optimal conditions for particle production, 
electrospray variables such as polymer concentration, voltage, tip-to-collector 
distance and flow rate were varied (section 1.3.1.3). Due to the fact that 
ultimately, fully biocompatible drug delivery systems are desired, particles were 
prepared using (the relatively less toxic) ethyl acetate solvent to dissolve GluN-
LLA and PLA polymers. An experimental setup similar to the one illustrated in 
Figure 1.3 was employed to produce the particles. Particle size and morphology 
was characterized by the processing of SEM images with Gimp 2.8 software. It 
was determined that the simplest way to achieve particle size control was by 
varying polymer concentration. Preliminary tests using the GluN-LLA oligomer 
were performed at three different weight/volume percentages: 5, 10 and 15 (Fig. 
3.1), while keeping flow rate in all cases at 0.5 mL/h. It is clear that at 5 kV, 
average particle diameters increase (0.79, 0.91 and 2.62 µm) with increasing 
polymer concentration, and that the particle size distributions (PSDs) were 
relatively broad in all samples (standard deviation: 0.94, 1.01, and 1.88, 
respectively). Increasing the processing voltage to 10 kV resulted in decreased 
average particle diameters (Fig. 3.1B). 
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The polymer concentration was then fixed at 5 %, and the flow rate was varied 
from 0.2 to 0.5 mL/h, in 0.1 mL/h increments (Fig. 3.2). As it turned out, samples 
processed at 5 kV displayed a bimodal PSD, with 80% of particles being in the 
submicron region (Fig. 3.1, inset). This is normally indicative of either the 
presence of more than one mode of electrified jet breakup, or the occurrence of a 
“satellite” droplet formation mechanism [87]. At 10 kV, a practical PSD 
unimodality was achieved at a flow rate of 0.3 mL/h, with only 3% of population 
consisting of supramicron-sized particles. However, a tradeoff between 
unimodality and particle diameter (if the general goal of using EHDA is indeed 
making ultrafine particles) becomes apparent, as the former comes at the 
expense of making larger particles (Fig. 3.2B).  
 
Since in this dissertation, one objective was to focus on drug release from well-
defined PSDs, it was preferred to process the samples at a flow rate 0.3 mL/h 
and voltage of 10 kV. Interestingly, increasing the voltage to 15 kV did not lead to 
smaller particle diameters. This effect is attributed to a multi-jetting mode being in 
operation exclusively at 10 kV. The single-jet mode was observed at 5 and 15 kV. 
The latter normally leads to larger particles relative to cases in which more than 
one electrified liquid jet is ejected from the Taylor cone. This same trend was also 
observed during the attempts to optimize the microparticle design from GluN-LLA 
and HMW PLA, which suggests that this may be a characteristic of the solvent 
system, rather than a solute effect. 
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Figure 3.1. Control over particle size is achieved by varying the concentration of 
GluN-LLA. Samples were solubilized in ethyl acetate and processed at 0.5 mL/h 
flow rate and voltages of: A) 5 kV, B) 10 kV. With increasing voltage, the average 
particle size decreases while particle diameter distribution becomes narrower. 
Increasing polymer concentration increases the average particle size (◄). Box 
range: 10-90%, whisker range: 5-95%, (x) 1-99%, (−) min. and max. values of 
particle diameter within investigated population. Inset: bimodal particle size 
distribution for sample prepared using 5 % w/v GluN-LLA concentration. Particle 
diameter means are significantly different (p<0.01) at 5kV and 10kV. 
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Figure 3.2. The effect of processing conditions, flow rate and voltage (A: 5 kV, B: 
10 kV) on particle size and distribution. Particles were prepared using a 5% (w/v) 
solution of GluN-LLA in ethyl acetate. Processing at 5 kV resulted in a bimodal 
particle size distribution with 80% of the population in sub-micrometer range. Box 
range: 10-90%, whisker range: 5-95%, (x) 1-99%, (−) min. and max. values of 
particle diameter within investigated population Box plots present submicron 
populations exclusively. Particle diameter means are significantly different 
(p<0.01) at 5kV and 10kV. 
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3.2. Fabrication of Pure, and RIF-loaded Submicron- and Micron-sized 
Particles 
 
The main objective of the in vitro drug release studies was to gain some insight 
into the difference in behavior between the GluN-LLA and a broadly accepted 
benchmark, LLA. Submicron particles based on LMW PLA (SMP-LLA) were 
prepared from their 5% (w/v) solutions in ethyl acetate at the chosen processing 
conditions (0.3 mL/h, 10 kV, 10 cm). In order to guarantee complete polymer 
dissolution and avoid precipitation, the solution needed to remain at 40°C during 
processing. The average particle diameter is somewhat smaller than those of 
their branched counterparts (Table 3.1).  
 
For the preparation of MP-LLA, a concentration of 1% (w/v) of HMW PLA was 
found to be very close to the polymer’s solubility. Thus, this value was selected 
for sample production under the same processing conditions. The MP-LLA in this 
case were characterized by a toroidal shape (Fig. 3.3) which, based on gained 
experience, is typically indicative of rapid solvent evaporation leading to imploded 
“doughnut”- or “raisin”-shaped particles. On the other hand, virtually perfect 
spherical MP-GluN-LLA are obtained with 20% (w/v) of GluN-LLA in ethyl acetate 
when processed at a flow rate (Q) of 0.5 mL/h, voltage (V) of 10 kV, and 
electrode-to-electrode distance (d) of 10 cm electrode-to-electrode distance (Fig. 
1.3 and Fig. 3.3). For the preparation of SMP-GluN-LLA, a 5% (w/v) GluN-LLA in 
ethyl acetate solution was used, which was processed under the same EHDA 
conditions as their SMP-LLA counterpart (Q = 0.3 mL/h, V = 10 kV, do = 10 cm). 
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The size and shape of the particles are crucial factors for delivery into the 
pulmonary airways: particles with aerodynamic diameters between 1-5 µm are 
preferred [49,88]. Particles with sizes larger than 5 µm are usually deposited in 
the oral cavity, and particles smaller than <0.5 µm move by Brownian motion and 
settle slowly. Nanoparticles (<100 nm) are not likely to deposit effectively in the 
pulmonary airways because they are exhaled before deposition [49]. In this work, 
two size ranges were intentionally made: SMP between 0.5 to 0.8 µm and MP 
between 2 to 3 µm. In the past, equipment modifications to the EHDA system 
were found to be necessary for particle micro-sizing i.e., to extract a fraction of 
nearly monodisperse PLGA microparticles in situ, at the expense of a decreased 
process efficiency [38]. In this dissertation, nearly monodisperse microparticles 
were prepared without using any EHDA apparatus modification, and the particle 
diameter ranges achieved fall within the targeted size ranges for the intended 
drug delivery long-term application i.e., inhalation.  
  
  
54 
 
Table 3.1. Polymers used in RIF release studies. Type, molecular weight (Mn), 
processing solution concentrations and diameters (average ± SD) of pure and RIF-
loaded particles are presented. Voltage: 10 kV, and flow rate: 0.3 mL/h were used 
unless specified otherwise 
Polymer 
Molecular 
weight, 
Da 
Concentration, 
% 
Particle diameter, µm 
   Particle type
c
 Pure polymer 1:5
a
 1:1
a
 
GluN-LLA 3,100 5.0 SMP-GluN-LLA 0.50±0.30 0.57±0.45 0.90±0.70 
  20.0
b
 MP-GluN-LLA 2.10±0.60 – – 
LMW PLA 2,500 5.0 SMP-LLA 0.37±0.30 0.87±0.80 1.22±1.0 
HMW PLA 123,000 1.0 MP-LLA 2.90±0.90 – – 
 
a) RIF-to-polymer mass ratio used to prepare particles, i.e. 20% and 50% by weight, 
respectively. 
b) Flow rate 0.5 mL/h was used. 
c) SMP: submicron particles, MP: microparticles 
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Figure 3.3. MP-GluN-LLA (A) and MP-LLA (B) were prepared at discrete 
voltages as indicated in respective plots. There are statistically significant 
differences between all populations within the subsets A and B (p < 0.01). Insets 
show the difference in particle morphology between low and high molecular 
weight polymers prepared at 10 kV. Spherical MP-GluN-LLA resulted from 
processing 20% (w/v) GluN-LLA (A). MP-LLA with toroidal shape were obtained 
by using 1% (w/v) HMW PLA (B). Average particle size (◄), box range: 10-90%, 
whisker range: 5-95%, (x) 1-99%, (−) min. and max. values of particle diameter 
within investigated population. 
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To evaluate the effect of drug loading on particle morphology (Fig. 3.4) and their 
PSD (Fig. 3.5), tests were performed for SMP-GluN-LLA and SMP-LLA at two 
drug loadings, namely 20 and 50 wt%, which correspond to RIF-to-polymer mass 
ratios of 1:5 and 1:1, respectively (Fig. 3.4). It has been mentioned that very high 
drug loadings and slow release profiles are two extremely desirable traits, and 
this is exactly the reason why attention has been aimed on such high RIF 
payloads. 
 
At 20 wt% loading, the broadening of the PSD in this sample (5/1, SMP-LLA) and 
that of the control differ in a statistically significant manner (*p<0.01), but this was 
not observed in the SMP-GluN-LLA sample, as shown in Figure 3.5 panels A and 
B. A loading of 50 wt% (5/5) resulted in further particle diameter increases, and in 
broadening of the PSDs, which could be a consequence of the higher 
concentration of polymer in the precursor solution. Differences in the particle 
diameters of SMP-LLA and SMP-GluN-LLA were found to be statistically 
significant at **p<0.01. An increased occurrence of general surface irregularities 
have previously been observed (e.g., particles with wrinkled surfaces) in PLGA 
microparticles with increasing RIF loading [38]. It is note however, that this is not 
indicative of phase separation: in this work case, separate RIF crystals were 
never observed by SEM. 
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Figure 3.4. SEM images illustrating the gradually changing morphology of 
polymeric submicronparticles made of low molecular weight polymers as RIF 
content is increased: SMP- GluN-LLA (top row) and SMP-LLA (bottom row). Pure 
polymeric particles (A, D) and with RIF-to-polymer mass ratios of 1:5 (B, E) and 
1:1 (C, F) are presented. The scale bar (10 µm) is the same for all images, 
except E (25 µm). 
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Figure 3.5. The effect of RIF loading expressed as polymer-to-RIF mass ratio, 
average diameter and particle size distribution. Two low molecular weight 
polymers were tested: A) SMP-GluN-LLA made with branched GluN-LLA, and B) 
SMP-LLA made with linear LMW PLA. Particles were prepared at a flow rate of 
0.3 mL/h and voltage of 10 kV. There are statistically significant differences 
between SMP-GluN-LLA and SMP-LLA (5/5 polymer to RIF ratio) when 
compared with their controls, subsets A and B (**p<0.01). At the 5/1 ratio, only 
the SMP-LLA were statistically significant different when compared with its 
control (*p<0.01). Average particle size (◄), box range: 10-90%, whisker range: 
5-95%, (x) 1-99%, (−) min. and max. values of particle diameter within 
investigated population. 
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3.3. Drug Entrapment Efficiency 
 
Time-release profiles from polymeric drug-loaded nano- and microparticles are 
usually characterized by a set of basic stages: (1) initial burst release, (2) slow 
diffusion-controlled release and sometimes, a (3) phase of abrupt release caused 
by a final loss of structural integrity in the particles. Burst release occurs in the 
first few hours, and it is commonly attributed to the fraction of drug located closer 
to the particle surface. The objective in this experiment was to determine the 
amount of drug that remains after this initial release had happened. While GluN-
LLA and PLA polymers are insoluble in ethanol, RIF solubility is 10 mg/mL. Thus, 
in order to extract the drug from the outermost layers of the particle surface, RIF-
loaded particles were contacted with ethanol for 10 minutes. After ethanol 
treatment, particles were fully dissolved and their remaining RIF content was 
determined. The RIF loading efficiency measured by this ethanol leaching test 
indicates that the GluN-LLA polymer is superior to its linear homopolymer 
counterparts irrespective of molecular weight and characteristic dimensions of 
the particles (Table 3.2). These results correspond to the amount of RIF retained 
within the particles at the end of the initial 8-hour period when PBS was used. 
The entrapment efficiency in the microparticles is comparable to those of RIF-
loaded PLGA microparticles prepared via the oil-in-water emulsification method 
(57-78% for PLGAs with molecular weights of 10 and 20 kDa) [40]. They are also 
well above those reported with RIF-loaded HMW PLA microparticles prepared via 
the supercritical anti-solvent method performed at comparable drug-to-polymer 
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ratios (40-50%) [55]. In general, the encapsulation efficiency calculated from 
cumulative release curves well exceeded 90% for all tested LMW systems (Table 
3.2), but is extremely low for HMW PLA. This is an expected result, as the low 
degradation rates of this class of polymers often results in permanent drug 
entrapment inside polymer network [63].  
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Table 3.2. Encapsulation efficiency and kinetic parameters of RIF release from L-
lactide based polymeric submicron and microparticles (n = 3). 
 
 
Polymer 
RIF: 
polyme
r ratio 
 
Typed 
Encapsulation 
efficiency, %a 
RIF 
release 
efficiency, 
%b 
Korsmeyer-Peppas 
equation fitting resultsc 
n k R2 
GluN-LLA 
1: 5 SMP-GluN-LLA 56.0±0.1 97.5 0.13 0.29 0.90 
1:10 SMP-GluN-LLA - 96.6 0.15 0.28 0.90 
LMW PLA 1: 5 SMP-LLA 15.0±0.2 98.3 0.71 0.14 0.99 
GluN-LLA 
1: 5 MP-GluN-LLA 71.0±1.7 93.1 0.14 0.33 0.95 
1:10 MP-GluN-LLA - 98.1 0.22 0.25 0.93 
HMW PLA 1: 5 MP-LLA 52.0±0.9 7.0 0.10 0.54 0.98 
 
a) The drug was extracted with pure ethanol for 10 minutes and the remaining solid 
was analyzed via 1H NMR. 
b) Results based on initial (6 and 12 µM for samples with 1:10 and 1:5 RIF-to-polymer 
mass ratios, respectively) and cumulative drug loading. 
c) Mt/M∞ = kt
n, where k is the constant incorporating characteristics of the 
macromolecular network system and the drug , n is the exponent describing release 
mechanism, Mt/M∞ is the fraction of the drug released at time t. 
d) SMP: submicron particles, MP: microparticles (see Table 3.1 for details). 
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3.4. Rifampicin Release from Submicron- and Microparticles 
 
The submicron- and micron-sized particles prepared with the GluN-LLA material 
as carrier yielded the desired results i.e., they were efficient in releasing the drug 
over a period of two weeks (Fig. 3.6). This efficiency was attributed to molecular 
interactions between RIF and the polymeric matrix. Linear polymers appeared to 
be less efficient than their branched counterparts in yielding strong molecular 
interactions with the drug. SMP-LLA prepared using a LMW PLA with a similar 
molecular weight to that of the glucosamine based oligomer allowed sustained 
drug release for 30-40 hours, as shown in Figure 3.6. However, as much as 60% 
of the drug was released within the first 8 hours. Similar results have been 
reported for PLGA (Mw = 5-15 kDa) submicron-size particles loaded with 
budesonide (MW= 430.5 Da) [89], and for RIF-loaded PLGA microparticles [40]. 
Increasing particle sizes from 165 nm to 289 nm extended the drug release time 
from 25-30 hours to 60 hours. Notably, submicron-particles (diameters: 169, 289 
and 400 nm) prepared by these authors using a core-shell electrospray (with a 
coaxial, two-liquid nozzle) approach lost 60-40% of the initial drug payload in just 
5 hours. This was found to take place despite the protection provided by a shell 
made of PLGA (100% drug encapsulation). The fact that these authors used the 
same drug release protocols as used in this dissertation is of utmost importance 
when comparing results from different sources. For example, it has been 
demonstrated that stirring speed significantly affects the dissolution rate profiles 
of RIF-loaded PDLLA microparticles [71]. 
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Figure 3.6. Cumulative RIF release curves from submicron and microparticles. 
Release curves correspond to SMP-GluN-LLA (▲), MP-GluN-LLA (♦) with RIF-to-
polymer mass ratios of 1:10 and SMP-GluN-LLA (Δ), MP-GluN-LLA (◊), SMP-LLA 
and MP-LLA (star symbols) with RIF-to-polymer mass ratios of 1:5. Insets show 
the release profiles during the first 8 hours. Data represent means ± SE (n=3). 
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There is little difference between the drug release kinetics from nano- and 
microparticles made of GluN-LLA at 10 wt% and 20 wt% payloads (curves SMP-
GluN-LLA (1:10) and MP-GluN-LLA(1:5) in Fig. 3.6, respectively). The ability of 
the new polymers to stabilize high drug payloads is also a most desirable trait, 
and it suggests the occurrence of a similar release mechanism for both particle 
diameter groups. This is consistent with particle size-encapsulation efficiency 
relationships reported by others [89]. 
 
For all samples, two stages of RIF release can be identified; an initial one, up to 
8 hours (Scheme 3.1, Step 1 and Fig. 3.6, insets), and a delayed phase, from 8 
to more than 300 hours (Scheme 3.1, Step 2 and Fig. 3.6). It is also apparent 
that the RIF release from SMP-LLA was mechanistically different than that from 
the GluN-LLA materials. This could be attributed to their different molecular 
architectures and functionalities, since both polymers have very similar molecular 
weights (Table 3.1). For LMW PLA, the drug release followed an anomalous, 
non-Fickian diffusion model (n = 0.71, Table 3.2) as defined by Ritger and 
Peppas (0.43 < n <0.85) [26,29]. The Korsmeyer-Peppas equation (see 
annotation c in Table 3.2 for details) predicts a diffusion-controlled drug release 
mechanism for systems with diffusion exponent ‘n = 0.43’. All tested GluN-LLA 
submicron- and microparticulate systems have much lower n-values (0.13-0.22, 
Table 3.2). This is indicative of drug-polymer matrix interactions [27], and these 
results are also consistent with encapsulation efficiency tests and DSC results 
(discussed next section). 
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Scheme 3.1. Representation of the bimodal kinetics of RIF release from the 
GluN-LLA carrier: 1) initial, 2) delayed. In the delayed phase the drug passes 
through pores created by molecules released in the initial phase (k1 > k2). In 
both phases the effects of drug-polymer interactions were evident and seen as 
decreased values for the n exponent in the Korsmeyer-Peppas equation (Table 
3.2). 
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3.5. Particle Degradation and Thermal Properties: Impact on Drug Release 
Kinetics 
 
The degradation studies performed under identical conditions as those from drug 
release measurements revealed that L-lactic acid (LLA) release is proportional to 
the available contact surface between polymeric particles and the solution (Fig. 
3.7). All tested polymers are hydroxyl-terminated and on a molecular level, the 
degradation mechanism for these polymers is end chain scission [90]. Both types 
of nanoparticles exhibited similar degradation curves, but after two weeks the 
LLA concentration was higher for SMP-GluN-LLA, 8.2 x 10-3 mM, than the 4.0 x 
10-3 mM observed with SMP-LLA. Overall, material loss due to degradation 
accounts for only 5% of the initial mass in 14 days of experiment, and thus has 
negligible effect on the RIF release mechanism. 
 
The DSC measurements revealed that the RIF used in this dissertation is the 
stable type I form (a single, sharp exothermic signal, peaking at 253°C is the only 
feature in its thermograms) [91]. The glass transition temperatures (Tg) for RIF-
loaded submicron- and microparticles prepared with GluN-LLA increased by 8-
10°C when compared to that of the pure polymer (Fig. 3.8 thermograms b, c and 
d) [1]. This is indicative of enhanced drug-polymer molecular interactions, i.e. RIF 
likely binds to terminal hydroxyl groups of GluN-LLA chains, thereby increasing 
its “effective molecular weight”, as evidenced by augmented Tg values. On the 
other hand, introduction of RIF is less likely to be responsible for the observed 
differences in thermal properties between pure and drug-loaded LMW PLA 
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nanoparticles. The as-prepared material is highly crystalline and there is no 
distinguishable characteristic glass transition inflection point seen in its 
thermogram (Fig. 3.8 f). However, rapid solvent evaporation during processing 
results in semi-crystalline features: Tg (46 °C) and an exothermic “cold 
crystallization” peak at 77°C were followed by an endothermic melting peak at 
133°C. If the drug occupied exclusively the limited available amorphous polymer 
regions and molecular interactions were thus very weak or absent, then it would 
be rapidly released upon contact with the PBS solution (Fig. 3.7) or ethanol 
(Table 3.2). 
 
Differences in molecular architecture have a pronounced effect on the thermal 
properties of these polymers: while GluN-LLA is purely amorphous, as evidenced 
by the previously reported DSC results, Tg = 43.7±1.3°C and the absence of the 
melting peak of the crystalline phase [1], the LWM PLA has semi-crystalline 
characteristics (Fig. 3.8 f) [92]. The DSC results suggest that chain length is a 
decisive crystallinity control factor for oligo-L-lactides, and transition from an 
amorphous to a semi-crystalline form takes place for monomer numbers higher 
than 10-12. In view of the results presented in this thesis, the advantages of 
using branched over linear molecular architectures for RIF delivery applications 
are apparent. The fine-tuning of the polymeric matrix crystallinity (a strategy that 
is sometimes used as an important drug release control factor) requires detailed 
knowledge of its thermal properties, and often demands the use of an additional 
post-processing step [93]. In matrices with reduced crystallinity, drug-polymer 
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interactions are enhanced. This in turn, leads to efficient dispersion of the drug 
within the polymer matrix, making these systems favorable for applications 
requiring slow release of the drug [94]. The current polymeric materials have 
potential for designing ultrafine particle based tuberculosis treatment systems: a 
typical tuberculosis treatment lasts about 6 months [4,7].  
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Figure 3.7. Semi-log plot of degradation of submicron- (open symbols) and 
micron-sized particles (filled symbols) prepared using linear (left panel) and 
branched (right panel) L-lactide based polymers. The release of L-lactic acid was 
tracked via 1H NMR spectroscopy. Data represent means ± SE (n = 3).  
 
 
 
70 
 
 
 
Figure 3.8. DSC thermograms. a) RIF, b) as prepared GluN-LLA polymer, c) RIF 
loaded SMP-GluN-LLA, d) RIF loaded MP-GluN-LLA, e) RIF loaded SMP-LLA f) 
as prepared LMWPLA. For samples c-e the RIF-to-polymer ratio was 1:5. 
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3.6. Particle Toxicity on M. Smegmatis 
 
Chitosan, the polymeric form of glucosamine, has been regarded as a 
biomaterial with bactericidal properties [95,96]. Melake et al. [97] reported on its 
cytotoxic effect on P. aeruginosa, with LMW chitosan showing a higher 
bactericidal activity compared to its medium and high molecular weight forms. 
Also, Liu et al. found higher cytotoxic effects with high molecular weight chitosan. 
The most accepted mechanism of its antibacterial action is believed to involve 
the positive charge of the protonated amine groups [98].  
 
Figure 3.9 shows the changes in % of growth area compared to control for SMP-
GluN-LLA, MP-GluN-LLA, SMP-LLA and MP-LLA at 300, 600 and 1,200 µg of 
particles/mL. It was hypothesized a priori that the presence of a glucosamine 
core in GluN-LLA was going to possibly contribute some antibacterial activity on 
M. smegmatis, but as shown in Fig. 3.9, this was not the case. Changes in 
bactericidal activity for all particle types and for all concentrations were not 
statistically different when compared to the control.  
 
However, significant statistical differences exist among particle materials (MP-
GluN-LLA vs MP-LLA, # p<0.01). While GluN-LLA particles do not affect bacteria 
survival, MP-LLA seems to favor M. smegmatis growth. This can be explained by 
the high correlation between microbial adhesion and the hydrophobic/hydrophilic 
characteristics of the interacting surfaces. In this regard, it has been shown that 
the adhesion of bacteria to solid surfaces is positively affected by the surface’s 
hydrophobicity [99,100]. Oliveira et al. performed adhesion experiments between 
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different bacteria and polymeric surfaces. These authors found surface 
hydrophobicity to be proportional to the number of adhering bacteria [101]. Thus, 
it is hypothesized that MP-LLA promotes bacterial growth compared to MP-GluN-
LLA, and that bacterial adhesion to MP-LLA particles possibly facilitated bacterial 
proliferation.  
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Figure 3.9. Particle toxicity on M. smegmatis. Mycobacteria were inoculated with 
different amounts of submicron- and micron-sized particles and were cultured for 
24 hours. 10μL of culture was placed onto agar plates and incubated at 37ºC for 
three days to see visible colonies. Colony area was quantified from agar plates 
pictures by ImageJ software. Statistically significant differences between SMP-
GluN-LLA and MP-LLA (+p<0.05); and between MP-GluN-LLA and MP-LLA 
(*p<0.05) at a particle concentration of 600 µg/mL, are shown. Statistically 
significant differences are shown between MP-LLA and MP-GluN-LLA, which is 
indicative of promoted bacterial growth by the linear LLA when compared to the 
branched GluN-LLA material (# p<0.01). Data represent means ± SE (n=3). 
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3.7. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal 
Concentration (MBC) of Free RIF and RIF Loaded Particles 
 
Table 3.3 summarizes the MIC and MBC results for free and encapsulated RIF 
and shows pictures of bacteria after 3 days of incubation in a 7H10 agar plate. 
These images were used to determine the MBC values. For particles loaded at a 
1:1 RIF-to-polymer mass ratio, SMP-GluN-LLA and MP-GluN-LLA showed MIC 
values that were about half of that of free RIF on a same dose of antibiotic basis. 
SMP-LLA showed MIC value 4 times lower than MIC value of RIF alone, while 
MP-LLA showed MIC value similar to that of RIF alone. MBC values were also 
affected by encapsulation: SMP-GluN-LLA and SMP-LLA showed MBC values 2 
times lower than free RIF, while MBC values for MP-LLA and MP-GluN-LLA were 
unaffected.  
 
Improved efficacy of antibiotics encapsulated in polymer particles and liposomes 
and intracellular delivery of antibiotics on different microbial strains has been 
reported. Mirzaee et al. [82] have found decreased values of MIC for 
encapsulated amikacin compared to free amikacin for E. coli, P. aeruginosa, S. 
faecalis and S. aureus. In the same manner, liposomes as encapsulants for 
amikacin, gentamicin and tobramycin reduced the MICs for highly antibiotics-
resistant strains while improving the uptake of antibiotics into the bacterial cells 
[83]. Meropenem and tobramycin encapsulated in liposomes inhibited the growth 
of bacteria using sub-MIC concentrations of antibiotic [84,102]. In both cases, the 
bactericidal activity of the antibiotics was increased when compared with that of 
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the free drug. One possible explanation for this phenomenon is membrane fusion 
between liposomes and bacteria, which would deliver a high dose of antibiotic to 
the microorganism and therefore surpassing the bacteria efflux pump capacity 
[103,104]. Another example where the bactericidal effect was also enhanced was 
shown by the use of RIF-loaded particles. PLGA microparticles loaded with RIF 
showed a greater bactericidal effect on Mycobacterium bovis Bacillus Calmette-
Guérin (BCG) in alveolar macrophages cells than that of RIF in solution at the 
same periods of time [53]. Similar results were obtained by Makino and 
coworkers [40], but in this case higher amounts of RIF were detected inside 
alveolar macrophages cells treated with RIF-loaded microparticles than when 
treated with RIF alone.   
 
Antimicrobial activity of the drug-free GluN-LLA and PLA particles was evident in 
figure 3.9, where it is shown that the RIF-free GluN-LLA particles present no 
antibacterial properties on M. smegmatis. However, MIC reduction in RIF-loaded 
GluN-LLA and SMP-LLA particles indicates an increase in bacterial killing relative 
to free RIF. The mechanism by which RIF encapsulation on GluN-LLA particles 
act this way has not yet been investigated. The physicochemical characteristics 
of the GluN-LLA polymer are reflected by the differences in the observed MIC 
values. At this stage, it is possible to speculate that surface charges of the 
polymer attract bacteria to the particle surface exposing them to a locally high 
antibiotic concentration. 
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Table 3.3 MIC and MBC values (μg/mL) of RIF in both free, and encapsulated forms 
were determined by the macrobroth dilution technique. Particles were produced with a 
1:1 RIF-to-polymer mass ratio. Images from agar plate of M. smegmatis incubated for 3 
days after contact with RIF-loaded particles and free RIF 
 
RIF concentrations (µg/ml) 
MIC  MBC 1 2 4 8 16 32 64 128 256 512 
Free RIF 64 256 
          
SMP-
GluN-LLA 
32 128 
         
 
MP-GluN-
LLA 
32 256 
          
SMP-LLA 16 128 
          
MP-LLA 64 256 
          
Amount particles 
(µg/ml) 
2 4 8 16 32 64 128 256 512 1024 
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3.8. Cytotoxicity of Particles on Macrophage Cells 
 
In order to determine the cytotoxicity of the four sets of particles, the WST-8 
viability assay was implemented. Figure 3.10 shows the survival rate (%) of 
macrophages after three days of incubation with the drug-free (no RIF) particles. 
Cytotoxicity was shown to be dose dependent i.e., at increasing particle doses 
there was an increase in cell death. Cytotoxicity was not significantly affected by 
the material type; at one specific dose level, all particle types showed a very 
similar effect. When comparing particle concentrations with the control, all particle 
types showed statistically significant differences at 120 and 240 µg/ml. At a 
concentration of 60 µg/ml, only SMP-GluN-LLA particles showed significantly 
different cytotoxicity levels in macrophages relative to its controls. The clear 
inhibition in macrophages proliferation that occurs at a particle concentration of 
120 µg/ml and at higher values can be due to an accumulation of free lactic acid 
in the culture media. As a product of polymer degradation, lactic acid could cause 
a localized lethal decrease in pH. This has been previously proposed to explain 
the cytotoxic effect observed with LLA grafted chitosan [2].  The cytotoxicity result 
(~20%) of SMP-GluN-LLA particles could be also correlated with its high cellular 
uptake (shown in Fig. 3.11), and smaller particle size. The increasing number of 
particles undergoing endocytosis could cause an increment in the production of 
reactive oxygen species (ROS), which can lead to toxicological effects. In 
addition, ROS generation is strongly favored by a decrease in particle size, which 
necessarily translates into an increase in specific surface area [105]. 
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Figure 3.10. Particle cytotoxicity on J774A.1 Macrophages. Different 
concentrations of GluN-LLA and LLA submicron and microparticles were 
incubated with macrophages for 3 days. The WST-8 reagent solution was 
contacted with the samples for one hour prior to OD450 measurement with a 
BioTek Elx800 microplate reader. Cytotoxicity of submicron and microparticles 
increased with increasing particle doses. All particle types’ cytotoxicity effects 
were statistically significant in terms of particle concentration when compared to 
their controls (*p<0.05). Data represent means ± SE (n=4). 
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3.9. Intracellular Localization of Particles by Confocal Microscopy 
 
Particle properties such as hydrophobicity, size, shape, and surface charge affect 
cellular uptake [106]. When particles are introduced in the growth media they 
adsorb various proteins. Hydrophobic surfaces produce denaturation of adsorbed 
proteins, which could negatively affect the particle uptake by cells [105]. After 
internalization, particles can follow two major pathways leading to programmed 
cell death (apoptosis), namely the death receptor, or the mitochondrial pathway 
[107]. The polyvalent surface of nanoparticles may induce cross-linking of cellular 
receptors, trigger signaling processes, induce structural alterations at the cell 
surface, and eventually interfere with normal cell function [108,109].  
 
Particle internalization and uptake into cells could lead to mitochondria swelling 
and an increase of mitochondrial membrane permeability which eventually 
causes mitochondrial dysfunction, ROS production, and initiation of an apoptotic 
signaling cascade [106]. In addition, upon internalization, particles could target 
lysosomes, leading to lysosomal membrane damage and dysfunction. It was 
reported that particle induced cell death is related to lysosomes localization in 
cancer cells [110]. Macrophages tend to engulf particles between 0.5-5 µm rather 
than nanoparticles. In addition, charged particles generally lead to better uptakes 
than uncharged particles [111]. In this study, GluN-LLA particles displayed higher 
uptake than PLA particles, as shown in Fig. 3.11.  
80 
 
 
Figure 3.11. Internalization of particle by macrophages. Submicron- and micron-
sized particles made out of GluN-LLA and LLA labeled with PCL-fluorescein were 
incubated with macrophages. Cells were washed and analyzed with confocal 
microscopy. The fluorescence intensity/cell of the different types of particles was 
quantified by ImageJ software. Macrophages showed statistically significant 
higher submicron- and microparticles uptake made with the branched GluN-LLA 
polymer than the particles made with the linear LLA polymer. Statistically 
significant differences (**p<0.01), and statistically significant differences when 
comparing with all populations (++p<0.01) are seen. Data represents means ± 
SE (n=4). 
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Previous studies showed that PLGA microparticles loaded with RIF colocalize in 
phago-lysosomes [112], suggesting that released RIF molecules diffuse first 
through the membrane of the phagosomes containing particles to the cytoplasm 
and then, also by diffusion, enter the phagosomes containing the bacteria. The 
particles studied in this thesis were internalized but surprisingly, did not 
colocalize in mitochondria or lysosomes. After phagocytosis, they remained in 
the cytoplasm (Fig. 3.12 parts A and B). What was found to be of critical 
relevance to the proposed medical application is that the absence of 
mitochondrial colocalization of particles is extremely desirable: if macrophage 
targeting is intended, particle colocalization in this organelle is expected to 
promote oxidative stresses that could lead to cell death. In these studies, particle 
cytotoxicity on macrophages was directly related to particle dose (Fig. 3.10). 
However, according to the results particle colocalization cannot be the culprit of 
these cytotoxic effects, as shown in Fig. 3.12 (A and B). A sustained release of 
RIF directly into the cytoplasm produces a strong concentration gradient within 
phago-lysosomes containing the bacteria. Therefore, RIF diffusion through the 
bacterial membrane and intracellular killing is highly improved. What is also of 
key relevance to the goals of this study is that GluN-LLA particles showed higher 
uptakes by macrophages compared to those made from LLA. This property can 
obviously be very desirable when considering the design of a macrophage-
targeting drug delivery system [79,113]. Thus, these polymers meet two 
important requirements for anti-tuberculosis drug delivery applications, namely a) 
high macrophage uptakes and b) low cytotoxicity. 
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Figure 3.12. Intracellular localization of particles. Mitochondria and Lysosome 
were stained with mitotracker and lysotracker, respectively. In order to be 
visualized particles containing PCL fluorescein were produced. Part A shows the 
images of lysosome stained cells: cytoplasm membrane staining (blue) and 
lysosome staining (red) after incubation with fluorescein loaded particles (green). 
Part B shows the images of mitochondria stained cells: mitochondria staining 
(red) after incubation with fluorescein loaded particles (green). Particles are 
engulfed by the cells but they do not colocalize either with mitochondria or with 
lysosomes i.e., they stay in the cytoplasm. The scale bar is 20 µm for all images. 
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3.10. Intracellular Killing of M. Smegmatis 
 
In order to evaluate the in vitro mycobactericidal effect of RIF-loaded GluN-LLA 
and PLA particles on M. smegmatis inside phagosomes, macrophages were first 
exposed to a high multiplicity of infection (MOI of 20 bacteria per cell) to facilitate 
infection, and after washing away the extracellular microorganism fraction, 
infected cells were contacted with RIF loaded particles (1:1 RIF-to-polymer mass 
ratio). For control and comparison purposes, free RIF and no-treatment samples 
were included in this experiment. To determine the intracellular killing 
effectiveness of free and encapsulated RIF, the ratio between the number of 
intracellular bacteria (c.f.u.) and the number of cells alive at the same time point 
was examined.   
  
The no-treatment control experiment, which can be seen as the inset of figure 
3.10, shows the cyclical behavior of killing/growth of M. smegmatis inside 
J774A.1 macrophages. This pattern has been observed by others [114,115]. The 
dynamic cycle of killing/growth phases is based on M. smegmatis’ ability to grow 
fast, and to significantly delay phagosome maturation for a few hours. After an 
exponential growth stage inside the macrophages, the mycobacterium is partially 
or totally killed by the macrophages, depending on the extent of infection [114]. 
Anes et al. observed this cyclic interplay between killing and surviving of M. 
smegmatis in J774 macrophages cultures with MOI values of 5-10, and within 48 
hours macrophages were able to kill M. smegmatis. In order to test the killing 
efficiency of a sustained release of RIF (from GluN-LLA particles) for a long 
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period of time (10 days), a very high MOI of 20 was used in this dissertation. 
Note that in the case of a pathogenic mycobacterium like M. tuberculosis, such 
high level of infection would naturally cause macrophage apoptosis, which in this 
context represents an innate defense against intracellular infection. Lee et al. 
studied macrophage apoptosis as a function of level of bacterial infection, and 
determined that M. tuberculosis rapidly induces cell apoptosis (90% in 20hrs) for 
MOI>10. Also, these authors’ study showed that M. smegmatis caused a minimal 
effect in macrophage death at MOI 25 and 50 [116].  
 
Since the objective of this experiment was to evaluate the performance of RIF-
loaded particulate systems, and to compare with free RIF for 10 days, the 
amount of free or encapsulated RIF added was half of the MIC measured (see 
table 3.3). Considering these experimental conditions, and the induced high 
infection levels, total killing of bacteria was not expected. One of this thesis’ goals 
was to determine the effect of prolonged drug release compared to free RIF. At 
half MIC, free RIF was very effective in killing intracellular bacteria during the first 
5 days, as shown by the linear dependence found between c.f.u/cell with time 
(Fig. 3.13). After day 5, a cyclic pattern was apparent, indicating a reduction in 
RIF effectiveness. In the case of encapsulated RIF, all systems showed an 
oscillatory behavior, with a significant reduction in c.f.u/cell values when 
compared to the control. Also, contrary to free RIF, particulate systems showed 
to be more efficient in killing bacteria after day 5. This result could be explained 
by the loss of bioavailability of free RIF in culture media at 37°C, where 50% is 
degraded after one week [117], while the encapsulated drug may be protected 
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against such degradation processes. The number of intracellular bacteria per cell 
in GluN-LLA and PLA polymers seems to be related to the RIF release 
mechanism. Both GluN-LLA and SMP-LLA systems presented higher number of 
intracellular bacteria per cell than free RIF during the first 4 days, but superior 
killing efficiencies after day 6. On the other hand, the MP-PLA polymer showed a 
different behavior: Like with free RIF, the oscillations in this case were strongly 
attenuated for the first 6 days, which is probably caused by the high burst release 
of the drug in this system (Figure 3.6, ~50% in 1 hr and ~70% in 8hrs). From 
these observations, it is clear that one can use these polymers to devise a drug 
release system, possibly a dual particle system, whose drug release profile can 
be engineered virtually at will. 
 
It is worthy of mention that after a thorough literature search, studies to assess 
the effect of RIF-loaded particles on M. smegmatis inside macrophages for more 
than one day were not found. To the best of the author’s knowledge, this 
dissertation presents, for the first time, an experiment to evaluate the 
performance of ultrafine particles on M. smegmatis inside macrophages as a 
tuberculosis model for 10 days, and with a daily sampling frequency. The reason 
for the scarcity of studies dealing with this particular problem is probably due to 
the fact that macrophages kill M. smegmatis in 48 hrs for MOI values ≤ 10. For 
example, Sonawane et al. [118–120] have done several antibacterial assessment 
of starch- and chitosan-coated silver nanoparticles on infected mouse 
macrophages (M.smegmatis, MOI=10). In their work, sampling of intracellular 
bacteria survival was usually performed between 6 to 8 hours after infection. 
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Figure 3.13. Intracellular killing of M. smegmatis. Macrophages were infected 
with M. smegmatis at an MOI of 1:20 (cells:bacteria). After infection 
macrophages were contacted with free RIF, and or RIF loaded particles. Inset 
shows control experiments where M. smegmatis showed a cyclic growth/killing 
pattern of colony forming units of intracellular M. smegmatis per macrophage cell 
in terms of time. 
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CHAPTER 4  
Conclusion and Proposed Future Research 
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4.1. Conclusions 
 
Using a new biocompatible polymer system based on glucosamine and L-lactide, 
submicron- and micron-sized particles loaded with RIF via an 
electrohydrodynamic atomization route were prepared. As comparator, low- and 
high-molecular weight poly-lactic acid materials were used. Control over particle 
size in a broad range was achieved by adjusting polymer concentration.  
 
A sustained RIF release from submicron- and micro-sized particles for 14 days in 
vitro was observed. These temporal profiles are composed of two clearly 
discernible stages: an initial drug release phase (up to 8 hours) from the 
outermost layers of the particles, followed by a delayed release phase. A nearly 
linear RIF release profile was observed for several days in the delayed phase for 
GluN-LLA submicron- and microparticles, and for the drug loadings of 10 and 
20%, respectively. After 14 days, degradation of the polymer matrix accounts for 
a loss of only 5% of the initial particulate mass, and its effect on the drug release 
mechanism is likely negligible. The Korsmeyer-Peppas equation represented the 
observed drug release behavior very well, which indicated that a modified 
diffusion-controlled release kinetics mechanism of RIF took place in all tested 
GluN-LLA systems. Low diffusion exponent values are indicative of enhanced 
drug-polymer matrix interactions. This is consistent with DSC results, i.e. a shift 
of 8-10°C towards higher temperatures in the observed glass transition 
temperature for drug loaded GluN-LLA particles. Drug encapsulation efficiency 
evaluated via ethanol leaching is also in line with the DSC findings. Four terminal 
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hydroxyl and one primary amine groups are present in GluN-LLA molecules, as 
opposed to just a single terminal hydroxyl moiety in the linear LMW PLA. 
Increased hydroxyl density could facilitate the enhancement of polymer-RIF 
interactions (five hydroxyl groups in the drug molecule) via hydrogen bonding. 
Thus, molecular affinity seemed to have been the dominant release mechanism 
in this case.  
 
Polymers that show high macrophage internalization without colocalization into 
different organelles are excellent candidates for the production of anti-
tuberculosis drug carrier particles. This was the case with glucosamine/L-lactide 
based polymers: the drug-loaded particles remain in the cytoplasm, releasing RIF 
in close proximity to intracellular bacteria. Intracellular killing of M. smegmatis by 
different particles showed a cyclic interplay between live and dead bacteria. The 
presence of free or encapsulated RIF at sub-MIC concentrations was effective in 
reducing the number of bacteria per cell compared to the control. It is suggested 
that the combination of different particle types and sizes involving at least one 
type of particle made from the new polymers used in this study will ultimately 
lead to the design of a system with optimal drug release profiles.  
 
This thesis’ overarching goal was to design a drug delivery system capable of 
attacking the microorganism over a long period of time and with just one dose. 
For a given set of chemical characteristics that could lead to carrier-drug 
interactions, polymeric materials with higher branching point densities and with 
amorphous structures may in principle extend RIF release times. The 
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development of such materials is an important area of research in the field of 
design of drug delivery systems for the treatment of tuberculosis. The in vitro 
results presented in this dissertation indicate that glucosamine/L-lactide 
polymeric systems are promising candidates for this particular application. 
4.2 - Proposed Future Work 
 
This dissertation has presented an approach for the development of a sustained 
drug delivery system as a potentially viable model for the treatment of 
tuberculosis. The proposed system is composed of biodegradable rifampicin 
(RIF)-loaded ultrafine particles. However, there would be certain areas to explore 
before the proposed drug delivery system can be developed into an effective 
nasal delivery vehicle for tuberculosis. This section will describe possible future 
directions in the evaluation of GluN-LLA ultrafine particles for RIF lung delivery.   
 
(1) In vitro evaluation of a Dual-Particle System. Section 3.10 in Chapter 3 
discusses the in vitro intracellular killing of the model bacteria from free and 
encapsulated RIF, and the superior performance of the particle system was 
demonstrated. In addition, and especially after Figure 3.13 is reexamined, one 
future experiment can be envisioned, namely the in vitro evaluation of a dual 
particle system for the RIF lung delivery as a treatment for tuberculosis. 
Specifically, a system containing MP-GluN-LLA and SMP-LLA would potentially 
combine the individual qualities of each particulate system. MP-LLA burst release 
would provide high extracellular RIF concentrations during the first eight hours of 
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the treatment (figure 3.6), and keep releasing the remaining drug in it over the 
course of 3-4 days. On the other hand, SMP-GluN-LLA (which undergoes 
endocytosis) would provide an intracellular sustained release of the drug for 
more than 12 days. Since drug release profiles of dual-particle systems can in 
principle be engineered at will, superior bacterial killing by such approach can be 
envisioned. In vitro drug release studies and intracellular killing evaluation using 
the procedures explained in sections 2.2.3 and 2.5.4 could then be proposed for 
the dual-particle systems listed in table 4.1. If one or two such systems showed 
improved behavior in vitro over the already tested single particle system, they 
would offer the possibility for advancing to an optimization stage, and ultimately 
toward in vivo research phase.     
 
 
Table 4.1. Dual particle systems (PDS) proposed for 
future experimentation 
PDS Particle combinations in a 1:1 ratio (initially)  
PDS-1 SMP-GluN-LLA and SMP-LLA 
PDS-2 MP-GluN-LLA and SMP-LLA 
PDS-3 MP-GluN-LLA and MP-LLA 
PDS-4 SMP-GluN-LLA and MP-LLA 
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For work beyond this dissertation, in vivo experimentation would be the next 
logical step to evaluate GluN-LLA nano- and microparticles for their intended 
purpose. To put things in perspective, in vivo studies have only demonstrated 
thus far sustained release of RIF from PLGA nanoparticles for up to 4 days (but 
via single oral administration [121]), so the need for improving these particle 
formulations for delayed release of RIF remains strong, and the need for 
investigating other forms of drug delivery (e.g., intranasal) remains unaddressed. 
 
The development of new polymeric material variants within this drug carrier 
family, for example with a higher degree of branching and amorphous structures 
that enhance RIF-matrix interactions, could in principle lead to additional 
improvements. In summary, the in vitro performance of GluN-LLA particles 
showed the essential features of high drug loading, slow sustained release, 
endocytosis by macrophages, MIC reduction, and intracellular killing of bacteria. 
These characteristics would warrant in vivo experimentation, even if these 
systems were by sheer luck, close to the optimum formulation. Such experiments 
are proposed below. 
 
(2) Intracellular killing assessment of M. tuberculosis in a mouse model. 
Animal handling and experimentation should be conducted following IACUC 
approval, standard protocols and approved guidelines. A mouse model is 
convenient and economical, yet with an animal size large enough to allow for 
drug administration, blood sampling and various tissue analyses and 
pharmokinetics [122–125]. For this study, Swiss mice would be infected with M. 
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tuberculosis H37Rv bacilli through the conventional aerosol route (Glascol 
inhalation route) [122–124], and randomly divided into an ideal set of groups as 
described in table 4.2. For statistic validation, each group would be composed of 
at least four animals, but ideally six. For comparison purposes, mice in control 
group 1 would not be treated with RIF, and groups 2-to-4 would receive “bank” 
particles (no drug) via the inhalation route. Animals in groups 5 to 13 would be 
treated weekly by inhalation of RIF-loaded particles at three doses levels (see 
Table 4.2). Group 14 would be composed by mice receiving free RIF orally seven 
days at a week. As it was mentioned before, a combination of GluN-LLA and PLA 
particles for the lung delivery of RIF is a priori promising, and for this reason, 
groups 4, 10 and 13 are optional, depending on their performance in in vitro 
experiments. Twenty one days after infection [123], each group would be treated 
as indicated in table 4.2.    
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Table 4.2. Proposed Swiss mice groups for in vivo experimentation for oral and 
inhalation treatments.   
Group Treatment would start 21 days post infection Treatment and 
dosage 
1 Untreated control No treatment 
2 SMP-GluN-LLA (weekly dose)  Inhalation Treatment 
with drug-free 
particles 
No RIF dose 
3 MP-GluN-LLA (weekly dose) 
4* PDS-X (weekly dose) 
5 RIF loaded SMP-GluN-LLA (weekly dose 1)  Inhalation Treatment 
with RIF-loaded 
particles 
Dose 1 = O x 7 = W 
6 RIF loaded MP-GluN-LLA (weekly dose 1) 
7* RIF loaded PDS-X (weekly dose 1) 
8 RIF loaded SMP-GluN-LLA (weekly dose 2) Inhalation Treatment 
with RIF-loaded 
particles 
Dose 2 =  W/2 
9 RIF loaded MP-GluN-LLA (weekly dose 2) 
10* RIF loaded PDS-X (weekly dose 2) 
11 RIF loaded SMP-GluN-LLA (weekly dose 3) Inhalation Treatment 
with RIF-loaded 
particles 
Dose 2 =  W/4 
12 RIF loaded MP-GluN-LLA (weekly dose 3) 
13* RIF loaded PDS-X (weekly dose 3) 
14 RIF (daily dose O)  Oral treatment with 
free RIF  
dose (O) would be 
administered daily 
per week W=O x 7 
*optional groups depending on previous dual particle systems in vitro 
experimentation  
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In order to demonstrate improvement over conventional oral treatment against 
tuberculosis in terms of patient compliance and drug side effects reduction, the 
weekly inhalation doses of RIF loaded GluN-LLA particles for groups 8-to-10 and 
11-to-13 would represent ½ and ¼ respectively of the weekly total free RIF orally 
administrated to group 14. Groups 5 to 7 would receive same amount of RIF than 
group 14 in a week. Thus, group 14 would receive an oral daily dose of 10 mg/kg 
of animal of RIF [122] for the entire course of the experiment (two weeks). Mice 
on groups 2 to 4, 5 to 7, 8 to 10 and 11 to 13 would be placed in a nose-only 
inhalation chamber (ADG Developments, Ltd, Herts, UK) to receive a weekly RIF 
dose loaded particles of 0, 70, 35 and 17.5 mg/kg of animal, respectively. SMP-
GLUN-LLA and MP-GluN-LLA particles with 1:1 RIF-to-polymer mass ratio would 
be employed for this experiment. One day after the completion of the two-week 
treatment, mice from all groups would be euthanized. Then, lungs and spleen 
would be harvested, homogenized and placed in appropriate cell culture medium 
for M. tuberculosis loads determination, as explained elsewhere [123,124,126].  
 
Results from this experiment would provide first-hand insight into the in vivo 
effectiveness of these particulate systems, and eventually point toward preclinical 
and clinical product development phases. Note that reductions of the recovered 
bacterial c.f.u. would be expected for all groups administrated with orally or 
inhaled RIF, when compared with the no administration of the drug (control 
groups 1 to 4). Likewise, any significant reduction, or even similar counting pf 
bacteria loads in groups 5 to 13 (inhalation treatment) as compared with group 
14 (oral treatment) would be taken as a positive result. As described in table 4.2, 
97 
 
when compared with oral treatment, RIF loaded particles used via the inhalation 
route should improve dosing regimen (less frequency) and groups 8-to-13 
decrease the amount of drug delivered to mice. These effects would lead to a 
decrease in side effects and improve compliance of the patients. 
 
Others in vivo experiments would be of interest, such as the (3) assessment of 
drug concentration in alveolar macrophages, and serum after administration 
of the ‘nose-only’ and oral RIF loaded particles [124,126]; and (4) phagocytosis 
activity by generation of nitric oxide (NO). These two tests are typically 
performed by analyzing the bronchioalveolar lavage (BAL) fluid that can be 
collected at several intervals after mice are dosed (only first dose in the treatment 
explained above). Parikh et al. [126]collected BAL from animals at intervals of 15, 
30, 60, 90, 120, 150, 180, and 240 minutes, which produced important 
information about drug uptake and phagocytic stimulation. The procedures to 
determine drug concentration in macrophages and NO from BAL fluid are 
available elsewhere [124,126]. 
 
As previously mentioned, the main advantage of lung delivery through inhalation 
therapy is the potential reduction of drug side effects, which is achieved by 
decreasing the amount of RIF delivered over the treatment period. This is 
possible as a result of avoiding first-pass metabolism and reducing renal 
clearance [127]. An adverse effect of RIF and the other first-line anti-tuberculosis 
drugs such as isoniazid, pyrazinamide and ethambutol often affects compliance 
of the patient [13]. The most serious side effect of RIF is hepatotoxicity, and it 
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should be the focus of any future in vivo toxicity studies our group may eventually 
desire to pursue. RIF toxicity can be assessed by a (5) study of liver functions 
such as serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic 
pyruvic transaminase (SGPT) [13,126]. Elevated levels of these enzymes in 
serum samples collected from mice groups would serve as indicative of liver 
damage. Other valuable set of toxicity tests would be the (6) histological 
examination of some organs after treatment, such as lung and liver. In brief, 
these tissues would have to be subjected to H&R staining, and then analyzed via 
high resolution microscopy [126].       
 
The ability to control side chain lengths (SCL) of the LLA building block in the 
GluN-LLA copolymer has been suggested in this dissertation as an important 
feature for tuning hydrophobic-hydrophilic characteristics of the particles. Table 
4.3 shows four GluN-LLA copolymers with different SCLs that have been 
synthesized in the past [1]. Since only GluN-LLA 1:32 has been investigated in 
this dissertation with excellent results, the possibility of future experimentation 
with formulation naturally arises. The working hypothesis would be that different 
SCL should lead to modified RIF-matrix interactions, and as a consequence to 
different drug release profiles. As starting point, ultrafine GluN-LLA RIF loading 
particles would be prepared using GluN-LLA 1:16, 1:24 and 1:40, and (7) in vitro 
drug release determination of new GluN-LLA particulate system would be 
performed. Results from this experiment would confirm the conclusions 
presented in this dissertation with regard to the mechanism of drug-matrix 
interaction, or provide new valuable information.  
99 
 
 
Table 4.3. Different molar ratios of LLA grafted glucosamine (GluN-LLA)  
GluN-LLA type Average Molecular 
Weight, Mn (H NMR) 
SCL 
1:16 1800 6.3 
1:24 2000 8.7 
1:32 3100 10.8 
1:40 3700 12.2 
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This dissertation has shown the possibility of producing an ultrafine GluN-LLA 
particle system as encapsulant for sustained release of RIF for more than 14 
days. These biodegradable particles showed biocompatibility and high 
endocytosis by macrophages, which are crucial characteristics for proposing new 
approaches to treat tuberculosis. However, the subject system proposes the 
intracellular killing of M. tuberculosis using RIF alone. In the conventional 6-
month treatment of tuberculosis, multidrug therapy is necessary to not only cure 
patients, but also to prevent the appearance of drug resistance strains. The 
World Health Organization (WHO) strongly recommends the use of multidrug 
treatments since monotherapy (use of a single drug) is one of the causes of the 
MDR-tuberculosis spreading [9]. For this reason, it is reasonable to propose as 
future work the following: (7) encapsulation of Ethambutol, Isoniazid and 
Streptomycin and (8) in vitro evaluation of multidrug systems on M. 
smegmatis. As it can be seen in Figure 4.1, streptomycin possesses an 
important number of –OH groups that could produce the hydrogen interaction 
needed to yield a strong drug-GluN-LLA interaction, with a concomitant slowing 
of the drug release kinetics for this particulate system. 
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Figure 4.1. First line anti-tuberculosis drugs 
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